



Cite this: *Lab Chip*, 2026, 26, 1191

Progress toward real-world diagnostic applications of microfluidic paper-based analytical devices (μ PADs)

Yohei Tanifuji^a and Daniel Citterio  ^{*ab}

Since their first report in 2007, microfluidic paper-based analytical devices (μ PADs) have continued to gain attention as promising tools for point-of-care diagnostics due to their low cost, portability, ease of operation, and design flexibility. This review summarizes and discusses recent advances in the field, mostly based on works published between 2017 and 2025, with a focus on progress and remaining challenges in bridging the gap between proof-of-concept demonstrations in academic laboratories and real-world implementation. Special emphasis is placed on devices validated with clinical samples and capable of true sample-in-answer-out operation. To comprehensively assess recent developments, nearly one hundred reported examples were analysed not only in terms of analytical figures of merit but also with respect to practical criteria such as real-sample testing, long-term storage stability, the need for off-device sample pretreatment, reagent handling complexity, time-control requirements, and the number of operation steps. In parallel, topics of ongoing academic interest are highlighted, including automated sequential reagent delivery, strategies for accelerating liquid flow, and robust signal readout methods going beyond purely qualitative approaches to enhance assay sensitivity, precision, rapidity, and instrument-free usability. Finally, the review introduces emerging analytical technologies newly integrated into μ PAD platforms, such as surface-enhanced Raman scattering (SERS), bioluminescence, CRISPR-based assays, and machine learning-driven data interpretation, which further expand the analytical capabilities and scope of μ PADs.

Received 25th November 2025,
Accepted 12th February 2026

DOI: 10.1039/d5lc01085c

rsc.li/loc

^a Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan.

E-mail: citterio@applc.keio.ac.jp; Tel: +81 45 566 1568

^b Faculty of Science, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand

Introduction

Starting from the earliest litmus paper pH tests in the 17th century, paper has been used as a versatile substrate for



Yohei Tanifuji

Yohei Tanifuji received his B. Eng. and M. Eng. degrees from Keio University in 2023 and 2024, respectively. He is currently carrying out PhD research focusing on the development of CRISPR/Cas-assisted microfluidic paper-based analytical devices.



Daniel Citterio

Daniel Citterio received his Doctoral degree in Natural Sciences from the Swiss Federal Institute of Technology (ETH) in Zurich (Switzerland) in 1998. After postdoctoral research at Keio University in Japan, a position as Research Associate at ETH Zurich and work at Ciba Specialty Chemicals in Basel (Switzerland), he returned to Keio University, where he became a tenured Associate Professor in 2009 and was promoted to full Professor in 2014. He is currently heading the Laboratory for Analytical Chemistry at the Department of Applied Chemistry. His research is focusing on the development of paper-based analytical devices (PADs) for low-cost point-of-need applications.



analytical assays for centuries. The introduction of urinary glucose dipsticks in the 1950s^{1,2} and lateral flow immunoassays (LFIAs) in the 1980s^{3,4} represent just two examples for the success in commercialization, emphasizing how a low-cost, mass-producible, and disposable material could be transformed into practical real-world analytical tools, including diagnostic devices. The currently ongoing massive development of paper-based analytical devices (PADs) in academic research laboratories was triggered back in 2007, when the Whitesides group introduced the concept of microfluidic paper-based analytical devices (μ PADs) by patterning of fluidic microchannels delimited by hydrophobic barriers on filter paper *via* photolithography.⁵ Their pioneering work demonstrated that paper could be used not just as a passive substrate for reagent immobilization, but as an engineered microfluidic platform capable of multiplexed assays, solid-liquid separation, and capillary-driven sample transport, eliminating the need for external pumps or power sources.

Following this breakthrough and continuing at present, μ PADs-related research has expanded rapidly across various fields of application including medical diagnostics, environmental monitoring and food safety testing, among others.^{6–8} The relatively low technical and economical barrier to entry in terms of device fabrication and cost, as well as the design flexibility has driven an explosion of proof-of-concept studies in the scientific literature, with the wax printing method as a representative and dominant paper patterning method.⁹ Reported works cover the full variety of signal detection techniques known from general analytical chemistry adapted to PADs, reaching from colorimetry to electrochemistry, fluorescence, bioluminescence and surface-enhanced Raman scattering, as well as a broad spectrum of targeted analytes ranging from small molecules, electrolytes, metabolites, nucleic acids, to pathogens. However, the enthusiasm and research activities in academia were not exactly matched by the adoption to real-world applications. The majority of reported μ PADs have only been evaluated under controlled laboratory conditions, often using simple aqueous solutions or target analyte spiked artificial samples just marginally mimicking real-world situations. This tendency limited the understanding of how such devices would perform when applied to complex, heterogeneous clinical specimens, where factors like viscosity, interfering substances, and matrix variability can significantly alter assay performance.

In 2017, we have published a comprehensive review summarizing and discussing the state-of-the-art in μ PADs for medical diagnostics in this journal.¹⁰ At that time, the technology was still in a developmental state. It was beyond the initial proof-of-concept stage but mostly not yet mature enough for broad deployment into clinical practice. We systematically analysed the reasons why, despite intense academic research activity, μ PADs still lagged in practical uptake compared with already established paper-based diagnostics such as lateral flow immunoassays (LFIAs).

Drawing from both the literature and publicly available market information, we identified several critical areas requiring focused improvement:

- Operational complexity and susceptibility to user error.
- Limited validation with real clinical samples and lack of interference studies.
- Insufficiently investigated long-term storage stability.
- Dependence on specialized detection equipment.
- Inconsistent and difficult-to-quantify signal readouts.
- Regulatory hurdles and competition with established diagnostics.

Since that time, the global context for rapid diagnostics has shifted dramatically. The COVID-19 pandemic brought LFIAs into the daily routine of millions worldwide, normalizing self-administered assays and increasing public familiarity with their operation and interpretation.^{8,11,12} This societal shift has not only lowered the psychological threshold for adopting paper-based devices but also raised expectations for their reliability, convenience, and affordability.

In terms of technological progress, most of the above-listed challenges have seen incremental rather than groundbreaking advances. However, a notable shift has emerged in the general development of μ PADs, marked by:

- A growing number of studies evaluating performance using real clinical specimens and thereby investigating potential interference from complex matrices.
- An increasing number of studies aiming at sample-in-answer-out operation, achieved by combining existing microfluidic architectures, detection chemistries, and sample pretreatment modules.

Even without fundamental breakthroughs, several performance-oriented areas have seen active development, particularly:

- Sensitivity and precision: improved through more advanced sequential reagent delivery strategies, with emerging designs automating reagent delivery *via* passive or active flow-control elements, reducing user intervention steps and improving analytical reproducibility.
- Rapidity: enabled by optimized or alternative fluidic pathways, capillary force control, and preloaded reagents, allowing to obtain results within minutes without sacrificing analytical performance.
- Long-term storage stability: supported by integration of nanozymes as replacement of natural enzymes.

Beyond operational performance, progress has also been made in signal interpretation. Initial μ PAD approaches were mostly reliant on external bulky devices (*e.g.* scanners, electrochemical workstations, *etc.*) used in combination with computers for quantitative data processing. On the other end of the spectrum remained the qualitative naked eye “yes/no” signal readout schemes (*e.g.* LFIAs), or simple comparisons with colour reference charts for semi-quantitative interpretation (*e.g.* urinary dipsticks). Recent years have seen a trend where researchers increasingly aim at either less subjective, hence more reliable semi-quantitative systems, or



quantitative analysis without use of bulky specialized equipment. This trend includes:

- (Semi-)quantitative systems: achieved by incorporating internal calibration zones and smartphone-based image analysis, to reduce user subjectivity and improve interpretation near decision thresholds.

In addition to these advancements, newly emerged analytical technologies have been integrated with μ PADs, such as:

- Signal detection methods including surface-enhanced Raman scattering (SERS) and bioluminescence.
- CRISPR-based assay techniques.
- Artificial intelligence integration represented by machine learning (ML).

In contrast to recent comprehensive reviews on μ PADs,^{7,13–15} the current critical review focuses on post-2017 developments mainly in the field of medical diagnostics. It highlights attempts to shift toward integrated, application-ready platforms and advancements in sensitivity, rapidity, and semi-quantitative readouts, as well as integration of newly emerged analytical technologies with μ PADs. Since the well-developed lateral flow immunoassay approaches are only marginally touched in this work, the reader is referred to related reviews for details of advancements in that field.^{11,16,17}

General progress in the field of μ PADs

Validation testing for clinical applications

A growing number of recent studies has moved beyond proof-of-concept demonstrations to report integrated μ PAD platforms capable of sample-in-answer-out operation, particularly in but not limited to the field of immunoassays and nucleic acid testing (NAT).^{18,19} The basic characteristics and the analytical performance of these devices, including the aspects of real sample pretreatment, are summarized in Tables 1–3, along with further details in Tables S1–S3, separated into devices for immunoassays, NAT, and other targets. As it is well known, biofluid samples represent complex matrices containing many compounds potentially interfering with a specific assay, such as for example proteins.²⁰ While the degree of clinical validation varies widely, the approaches employed for clinical sample testing with μ PADs can be broadly classified into four categories: (1) spiking known amounts of target analytes into artificial matrices mimicking clinical samples; (2) spiking known amounts of target analytes into real clinical sample matrices to evaluate recovery; (3) diluting clinical specimens with water or buffer; (4) applying off-device pretreated sample fractions such as serum, plasma, or extracted nucleic acid samples; and (5) directly analysing the raw clinical sample without any off-device pretreatment. From a point-of-care testing perspective, the last approach offers the greatest real-world relevance and acts as proof for eliminating the need for off-device sample preparation.

Looking at Tables 1–3, most reports demonstrated real sample applicability at least at the level of the above-mentioned category (1), by spiking target analyte into artificial biofluids. Factors contributing to successful real sample matrix tests without dilution include multiple washing steps in immunoassays, off-device nucleic acid extraction and purification, and the application of an additional running buffer after the raw sample is applied. In this context, paper-based immunoassays requiring neither off-device sample pretreatment nor multiple operation steps are outstanding. Examples rely on automated sequential reagent addition methods,^{21,22} or on bioluminescence resonance energy transfer (BRET) signaling,²³ details of which are introduced in following sections. In addition, paper-based NAT functioning without a need for off-device nucleic acid extraction are also noteworthy.^{24,25} However, there is still a room for improvement in terms of reagent handling and stability, long assay times, as well as a lack of real sample testing. When focusing on clinical sample matrices, blood serum is mostly used in immunoassays (Table 1), while blood serum, nasal swab samples and less frequently saliva are used in NAT (Table 2). On the other hand, whole blood samples are more commonly used in assays targeting routine health check parameters, such as glucose. This is partially attributed to biosafety and logistic challenges associated with obtaining and handling infectious disease samples, as well as the instability of whole blood samples, which makes it difficult to handle clinical samples outside of hospitals. When it comes to spiked samples, it is of importance to consider the practically relevant concentration range for real clinical samples (Tables S1–S3), a fact that is sometimes insufficiently addressed in publications.

Evaluation of sample-in-answer-out μ PADs

Reagent handling and device operation involved in assays are important aspects to evaluate their user-friendliness. Ideally, operations needed for end-users should be limited to only sample application (more ideally, volume-independent) and signal readout without any external equipment. Tables 1–3 also summarize the number of device operation steps, the absence or presence of reagent handling requirements and external equipment, and the assay time. Additional details are provided in Tables S1–S3. Table 1 summarizing μ PADs for diagnostic immunoassays reveals that they generally require more operation steps, such as washing and reagent addition, compared with other types of assays. Additionally, precise time control is often necessary during these multiple operation steps. On the other hand, as shown in Tables 2 and S2 covering NAT, it is often required to use external equipment, such as heaters or detection instruments to enhance assay sensitivity, in addition to relatively longer assay times. Compared with immunoassays and NAT, μ PADs relying on simple reaction mechanisms as shown in Table 3 require fewer operation steps and shorter assay times, since



Table 1 Recent examples of μ PADs (2018–2025) for medical diagnostic applications (immunoassays)

Analyte	Sample matrix	Real sample test	Sample type category	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment	Step #	Reagent handling	External equipment	Ref.
TNF- α	Rat tissue sample	Clinical sample (rat)	5	Colorimetric	N.A.	22 pM	N.A.	31 min	No	2	No	Yes	21
IL-6	Human saliva	Clinical sample	5	Coloured length	0.05–25.0 pg mL ⁻¹	0.05 pg mL ⁻¹	4 °C	35 min	No	5	Yes	No	44
SARS-CoV-2	Human urine				0.05 to 25.0 pg mL ⁻¹	0.05 pg mL ⁻¹	<12 weeks						
SARS-CoV-2	Exhaled breath		4	Echem (DPV)	3.7–10 000 ng mL ⁻¹ (Exhaled breath)	1 ng mL ⁻¹	4 °C	60 min	Yes	4	Yes	Yes	202
HBV	Human serum		4	Echem (CA)	0.1–250 ng mL ⁻¹	8.2 pg mL ⁻¹	>33 days	<500 s	Yes	3	No	Yes	69
HCV					0.001–250 ng mL ⁻¹	1.19 pg mL ⁻¹	-20 °C						
SARS-CoV-2			4	Colorimetric	N.A.	5 nM (Serum)	N.A.	15 min	Yes	5	Yes	Yes	203
			4	Colorimetric (DL assisted)	N.A.	N.A.	N.A.	<20 min	Yes	8	Yes	Yes	183
cTnI			4	Colorimetric (DL assisted)	Up to 100 ng mL ⁻¹	0.2 pg mL ⁻¹	N.A.	<15 min	Yes	8	Yes	Yes	185
			4	CL (DL assisted)	(Serum) 0.001–100 ng mL ⁻¹	(Serum) 0.16 pg mL ⁻¹	N.A.	25 min	Yes	9	Yes	Yes	193
Anti-Bb Abs			4	Colorimetric (DL assisted)	N.A.	(Serum) N.A.	N.A.	<15 min	Yes	6	No	Yes	178
			4	Colorimetric (DL assisted)	N.A.	(Serum) N.A.	N.A.	<20 min	Yes	6	Yes	Yes	184
Myoglobin			4	FL (DL assisted)	N.A.	0.52 ng mL ⁻¹ (Serum)	N.A.	<15 min	Yes	7	Yes	Yes	182
CK-MB						0.3 ng mL ⁻¹ (Serum)							
FABP						0.49 ng mL ⁻¹ (Serum)							
CRP	Human serum	Diluted clinical sample	3	Colorimetric (DL assisted)	0–10 mg L ⁻¹ (Serum)	N.A.	N.A.	<12 min	Yes	6	Yes	Yes	179
Anti-IFN- γ abs	Human serum	Diluted clinical sample	3	Colorimetric (DL assisted)	0.003–3 μ g mL ⁻¹ (PBS)	0.001 μ g mL ⁻¹ (smartphone)	N.A.	<10 min	Yes	3	No	Yes/no	22
SARS-CoV-2	Human saliva	Spiked into biofluid sample	2	Colorimetric (Saliva)	10–160 pg mL ⁻¹	10 pg mL ⁻¹ (PBS)	N.A.	8 min	No	8	Yes	Yes	204
cTnI	Human whole blood		2	Echem (EIS)	90 pg mL ⁻¹ to 90 ng mL ⁻¹ (Artificial blood plasma)	4.6 pg mL ⁻¹ (190 fM)	N.A.	46 min	No	9	Yes	Yes	55



Table 1 (continued)

Analyte	Sample matrix	Real sample test	Sample type category	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment	Step #	Reagent handling	External equipment	Ref.
BNP				Echem (EIS)	6 pg mL ⁻¹ to 6 ng mL ⁻¹	1.2 pg mL ⁻¹ (40 fM)							
D-dimer				Echem (EIS)	(Artificial blood plasma) 91 ng mL ⁻¹ to 91 µg mL ⁻¹	(Artificial blood plasma) 146 pg mL ⁻¹ (730 fM)							
HIV1	Porcine whole blood		2	BL	N.A.	2.8 nM (Porcine serum)	-20 °C >2 months	21 min	No	2	No	Yes	23
Hemagglutinin													
HBV						7.1 nM (Porcine serum) 19.3 nM (Porcine serum)							
HIV1	Human plasma		2	Colorimetric	0.03–3 ng mL ⁻¹ (Plasma)	0.03 ng mL ⁻¹ (Plasma)	N.A.	<10 min	Yes	6	Yes	Yes	30
α-Fetoprotein	Human serum	Spiked into biofluid sample	2	Echem (EIS)	0.01–500 ng mL ⁻¹ (9 min)	1.65 pg mL ⁻¹ (9 min)	4 °C	9 min	Yes	7	No	Yes	31
Procalcitonin	Synthetic serum	Spiked into artificial biofluid sample	1	AR (smartphone)	0.5 pg mL ⁻¹ to 10 ng mL ⁻¹ (30 min)	3.54 fg mL ⁻¹ (30 min)	<15 days	30 min	Yes	8	Yes	Yes	121
α-Fetoprotein	Buffer	N.A.	—	Echem (CA)	2–10 µg mL ⁻¹ (Serum)	2 µg mL ⁻¹ (Serum)	N.A.	84 min	Yes	8	Yes	Yes	41
PfHRP2	PBS	Spiked into biofluid sample	—	MS	10–100 ng mL ⁻¹ (KNO ₃)	0.63 ng mL ⁻¹ (KNO ₃)	N.A.	33 min	N.A.	5	Yes	Yes	205
					N.A.	5 nM (PBS)	N.A.	>10 min	N.A.	6	Yes	Yes	205

TNF-α: tumour necrosis factor-α, IL-6: human interleukin-6, HBV: hepatitis B virus, HCV: hepatitis C virus, cTnI: cardiac troponin I, anti-Bb Abs: anti-*Borrelia burgdorferi* antibodies, CK-MB: creatine kinase-MB, FAPP: fatty acid binding protein, CRP: C-reactive protein, anti-IFN-γ abs: anti-interferon-γ autoantibodies, BNP: brain natriuretic peptide, HIV1: human immunodeficiency virus type 1, HA: hemagglutinin, DEN1: dengue virus type 1, PfHRP2: plasmodium falciparum histidine-rich protein 2, DPV: differential pulse voltammetry, CA: chronoamperometry, EIS: electrochemical impedance spectroscopy, CL: chemiluminescence, FL: fluorescence, BL: bioluminescence, Echem: electrochemistry, AR: augmented reality, MS: mass spectrometry, DL: deep learning, r.t.: room temperature, N.A.: not available; sample type categories are: (1) spiking known amounts of target analytes into artificial matrices mimicking clinical samples; (2) spiking known amounts of target analytes into real clinical sample matrices; (3) diluting clinical specimens with water or buffer; (4) applying off-device pretreated sample fractions; and (5) directly analysing the raw clinical sample without any off-device pretreatment.

Table 2 Recent examples of μ PADs (2018–2025) for medical diagnostic applications (nucleic acid testing)

Analyte	Sample matrix	Real sample test	Sample type	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment	Step #	Reagent handling	External equipment	Ref.		
ctDNA	Mice serum	Clinical sample (mice)	4	Colorimetric	200–1500 pM (Serum)	95.81 pM (Serum)	4 °C >15 days	63 min	Yes	6	Yes	Yes	56		
SARS-CoV-2	Human saliva	Clinical sample	5	Colorimetric	N.A.	79.88 pM (Serum)	N.A.	60 min	No	5	Yes	Yes	24		
						50 copies μL^{-1} (Saliva)		40 min	Yes	4	Yes	Yes	39		
SARS-CoV-2 (Alpha, beta, delta, and gamma)	Swab	Clinical sample	4	FL	10^2 – 10^4 copies	10^2 copies	r.t. >30 days	52 min	Yes	5	No	Yes	79		
								Echem (amperometry) (PBS)	>4 weeks	Yes	5	Yes	Yes	28	
								Colorimetric	N.A.	400 copies per μL (Smartphone)	<30 min	Yes	Yes	Yes	28
								Colorimetric	N.A.	2400 copies per μL (Naked eye)	<30 min	Yes	Yes	Yes	28
HPV	Human saliva	Clinical sample	4	FL	1 – 10^5 fM	1 fM	N.A.	35 min	Yes	6	Yes	Yes	59		
								FL	N.A.	1–100 aM	40 min	Yes	Yes	Yes	169
								Echem (amperometry) (PBS)	0.05 – 1000 nM	0.35 pM	52 min	Yes	Yes	Yes	79
RSV	Human serum	Diluted clinical sample	4	Echem (SWV)	10 pM to 2 μM (PBS)	7.23 pM	4 °C >4 weeks	7 min	Yes	2	No	Yes	38		
Dengue virus	Human saliva	Spiked into biofluid sample	2	BL	N.A.	5 copies (Serum)	N.A.	~30 min	Yes	9	Yes	Yes	58		
								Colorimetric	10 copies (Serum)	<1 month <30 °C >30 h	<1 h	Yes	8	Yes	Yes
Zika virus Let-7a (miRNA)	Human saliva	Diluted clinical sample	4	BL	2 fM to 50 pM	1.7 fM	r.t. >3 months	150 min	Yes	4	Yes	Yes	86		
SARS-CoV-2	Human saliva	Spiked into biofluid sample	2	BL	N.A.	40 nM (Saliva)	r.t. <7 weeks	7–12 min	(Yes)	3	No	Yes	150		
								Colorimetric	N.A.	50 copies per μL (Saliva)	60 min	No	Yes	Yes	24
Influenza A virus	Human saliva	Diluted clinical sample	2	Colorimetric	N.A.	50 copies per μL (Saliva)	N.A.	60 min	No	5	Yes	Yes	24		



Table 2 (continued)

Analyte	Sample matrix	Real sample test	Sample type category	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment	Step #	Reagent handling	External equipment	Ref.
Influenza B virus HIV1	Human whole blood	Spiked into biofluid sample	2	FL	N.A.	3×10^3 copies per mL (Whole blood)	N.A.	30 min (on-chip) >10 min (post amplification)	Yes	7	Yes	Yes	207
MRSA	Blood	Spiked into biofluid sample	2	FL	$1-10^4$ copies (35 min) 10^2-10^8 copies (42 min)	1 copy (42 min)	r.t.	36 or 43 min	Yes	4	No	Yes	208
Chikungunya	Human serum	Clinical sample	2	FL	N.A.	10 copies (Serum) 17 aM	N.A.	<1 h	Yes	8	Yes	Yes	206
SARS-CoV-2	N.A. (aerosol generated by breathing artificial simulator)	Spiked into artificial biofluid sample	1	Colorimetric	N.A.	N.A.	N.A.	30 min (sample collection) ~1.5 h (on-chip)	No	2	No	No	25
Five pathogens (<i>E. coli</i> , <i>S. aureus</i> , <i>P. aeruginosa</i> , <i>K. pneumoniae</i> , <i>A. baumannii</i>) HIV1	Surface swab (mimicking bacterial contamination on bench) Human whole blood	Spiked into diluted biofluid sample	1	FL	$100-10^6$ copies per μL (PBS)	1 copy per μL (PBS)	N.A.	<60 min	No	5	No	Yes	209
Mpox virus	Artificial urine or saliva	Spiked into diluted biofluid sample	1	Colorimetric	N.A.	3×10^5 copies (whole blood)	r.t. >3 weeks	90 min	Yes	4	No	Yes	210
HPV16 HPV	N.A. Water	N.A.	—	Echem (SWV) Echem (personal glucose meter)	10–1000 copies per mL (Urine, saliva)	≈ 5 copies per mL (Urine, saliva)	55 °C >30 days N.A. –20 °C >4 weeks N.A.	<30 min 130 min 120 min	Yes (Yes)	5 6 4	Yes No	Yes Yes	90 211 177
Ebola virus	Water	Water	—	Coloured length	N.A.	11 aM	N.A.	285 min	Yes	4	Yes	Yes	171

ctDNA: circulating tumour DNA, HPV: human papillomavirus, RSV: respiratory syncytial virus, HBV: hepatitis B virus, miRNA: micro-RNA, HIV1: human immunodeficiency virus type 1, MRSA: methicillin-resistant *Staphylococcus aureus*, SWV: square wave voltammetry, EIS: electrochemical impedance spectroscopy, FL: fluorescence, BL: bioluminescence, Echem: electrochemistry, r.t.: room temperature, N.A.: not available; sample type categories: (1) spiking known amounts of target analytes into artificial matrices mimicking clinical samples; (2) spiking known amounts of target analytes into real clinical sample matrices; (3) diluting clinical specimens with water or buffer; (4) applying off-device pretreated sample fractions; and (5) directly analysing the raw clinical sample without any off-device pretreatment.

Table 3 Recent examples of μ PADs (2018–2025) for medical diagnostic applications (other targets)

Analyte	Sample matrix	Real sample test	Sample type category	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment	Step #	Reagent handling	External equipment	Ref.
Uric acid	Human saliva	Clinical sample	4	Colorimetric	0–214.8 ppm (Artificial saliva)	0.1 ppm (Artificial saliva)	4 °C >3 months	<10 min	Yes	4	No	Yes	92
Hemoglobin			5	Colorimetric	1.57–2000 $\mu\text{g mL}^{-1}$	1.57 $\mu\text{g mL}^{-1}$	r.t. >3 weeks	3 min	No	2	No	Yes	195
				Coloured distance	3–200, 200–2000 $\mu\text{g mL}^{-1}$	3 $\mu\text{g mL}^{-1}$							
Albumin	Human urine		5	Coloured distance	0–1000 mg L^{-1} (Artificial urine)	N.A.	r.t. >2 months	15 min	No	1	No	No	212
Creatinine					50.0–750 $\mu\text{g L}^{-1}$ (Artificial urine)								
Glucose	Human whole blood		5	Colorimetric	2.5–20 mM (Whole blood)	0.3 mM (Whole blood)	N.A.	10 min	No	2	No	Yes	213
			5	Colorimetric	50–365 mg dL^{-1} (PBS)	N.A.	N.A.	30 min	No	3	No	Yes	214
			5	Colorimetric	2.20–15.00 mM (Whole blood)	0.12 mM (Whole blood)	–4 °C <40 days	12 min	No	2	No	Yes	215
Urea			5	Colorimetric	2.46–38.14 mM (Whole blood)	0.03 mM (Whole blood)	35 °C >8 days	<2 min	No	1	No	Yes	216
Uric acid			5	Colorimetric	0–1.5 mM (Whole blood)	0.1127 mmol L^{-1} (Whole blood)	4 °C <28 days	>10 min	No	3	No	Yes	83
Creatinine					0–100 μM (Whole blood)	0.2978 $\mu\text{mol L}^{-1}$ (Whole blood)		>13 min					
Albumin					0–100 mg mL^{-1} (Whole blood)	0.7696 mg mL^{-1} (Whole blood)		>6 min					
Hemoglobin			5	Colorimetric	2.5–15 g dL^{-1}	2.5 g dL^{-1}	r.t. >8 h	<5 min	No	2	No	Yes	29
cTnI			4	Coloured distance	0.025–2.5 ng mL^{-1} (Whole blood)	0.025 ng mL^{-1} (Whole blood)	r.t. >10 weeks	15–30 min	Yes	2	No	No	85
Urea	Human saliva	Diluted clinical sample	3	Colorimetric	0.10–5.0 mM	0.032 mM	r.t. <1 months	35 min	Yes	3	No	Yes	84
NHx			3		0.16–5.0 mM	0.049 mM	r.t. <2 months	15 min			Yes		



Table 3 (continued)

Analyte	Sample matrix	Real sample test	Sample type category	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment	Step #	Reagent handling	External equipment	Ref.
Zinc(II)	Human urine	Spiked into biofluid sample	2	Colorimetric	50.0–750 $\mu\text{g L}^{-1}$ (Urine)	10 $\mu\text{g L}^{-1}$ (Urine)	r.t.	>5 min	Yes	2	No	Yes	217
Histidine	Human urine		2	FL-pixel	0.5–20 mM	0.021 mM	<7 days	>10 min	No	5	Yes	Yes	218
Glucose	Human serum		2	FL-distance Colorimetric	5–11 mM (Serum)	0.5 mM	N.A.	5 min (buffer)	(Yes)	2	No	Yes	78
Cholesterol					2.6–6.7 mM (Serum)	0.2 mM (PBS)		8 min (serum)					
Triglyceride					1–2.3 mM (Serum)	0.3 mM (PBS)							
Secnidazole			2	FL	0.1–300 μM	N.A. (117 nM in bulk)	N.A.	N.A.	(Yes)	3	No	Yes	219
ALP	Calf, human, goat serum		2	Echem (CA)	N.A.	1.4 U L^{-1}	r.t.	20 min (pre-reaction)	Yes	3	Yes	Yes	211
H ₂ O ₂	Artificial saliva	Spiked into artificial biofluid sample	1	Echem (CA)	0.25 μM to 5 mM	0.15 μM	>4 weeks	20 min (flow measurement)	No	2	No	Yes	220
Glucose			1		2.5 μM to 3 mM	1.5 μM	4 °C						
			1	Coloured distance (barcode)	15–200 mg dL^{-1} (Artificial saliva)	15 mg dL^{-1} (Artificial saliva)	<4 weeks	90 min	No	3	No	Yes	117
Ascorbic acid	Artificial urine		1	Colorimetric	0–20 mM (Artificial urine)	1 mM (Artificial urine)	N.A.	10–30 min	No	1	No	No	120
Lithium ion	Human whole blood		2	Echem (CA)	0.15–0.8 mM	92.8 μM	N.A.	250 s	No	2	No	Yes	41
			2	Colorimetric	0–2.0 mM (Whole blood)	0.281 mM (Whole blood)	N.A.	10 s	No	3	No	(Yes)	221
Dam MTase	Human serum	Spiked into diluted biofluid sample	2	FL	1.0–90 U mL^{-1}	0.11 U mL^{-1}	>10 days	35 min	(Yes)	4	Yes	Yes	60
NADPH	Simulated urine	Spiked into diluted biofluid sample	2	Echem (CA)	0.01–1.0 mM, 1.0–4.0 mM (Urine and serum)	3.75 μM	55 °C	<10 min	No	3	No	Yes	91
L-Tryptophan	Human serum		2	Colorimetric	0.25–1.5 mM	220.7 μM	N.A.	(5 samples with flow measurement)	(Yes)	5	Yes	Yes	222



Table 3 (continued)

Analyte	Sample matrix	Sample type category	Detection technique	Detection range	Detection limit	Storage stability	Assay time	Off-device treatment (Yes)	Step #	Reagent handling	External equipment	Ref.
Albumin	Human serum	2	Coloured distance, angle	1–25 g L ⁻¹	0.8 g L ⁻¹	N.A.	30 min		2	No	No	223
ALP		2		5–50 U L ⁻¹ and 50–200 U L ⁻¹	5 U L ⁻¹							
Serotonin	Buffer	—	Echem (CA)	1–20 mM	0.15 mM	N.A.	13 min	N.A.	5	Yes	Yes	41
cTnI	PBS	—	SERS	0–0.5 ng mL ⁻¹	0.02 ng mL ⁻¹	N.A.	<90 min	N.A.	3	No	Yes	224

cTnI: cardiac troponin I, ALP: alkaline phosphatase, Dam MTase: DNA adenine methylation MTase, NADPH: nicotinamide adenine dinucleotide phosphate, FL: fluorescence, echem: electrochemistry, CA: chronoamperometry, r.t.: room temperature, N.A.: not available; sample type categories: (1) spiking known amounts of target analytes into artificial matrices mimicking clinical samples; (2) spiking known amounts of target analytes into real clinical sample matrices; (3) diluting clinical specimens with water or buffer; (4) applying off-device pretreated sample fractions; and (5) directly analysing the raw clinical sample without any off-device pretreatment.

they eliminate the necessity for off-device sample pretreatment and reagent handling, demonstrating significant progress toward sample-in-answer-out systems.

When focusing on reagent handling across all types of assays, most μ PADs store at least some of the required reagents on the device, while potentially unstable reagents such as biological reagents, hydrogen peroxide, and ferricyanide/ferrocyanide are often not stored. Even when such reagents are pre-deposited on a device, their long-term storage stability is typically not investigated. Thus, parallel evaluation of both reagent handling and long-term storage stability is of great importance. For hydrogen peroxide, methods to prolong its shelf-life when stored on μ PADs using poly(vinyl alcohol) and titanium dioxide nanoparticles have recently been reported, enabling H₂O₂ storage for 30 days at 4 °C and at 25 °C, respectively.^{26,27} Similar basic evaluations to extend the storage stability of other specific reagents on μ PADs are also needed, if they play a critical role in assay reactions.

Similarly, the number of operation steps should be considered together with the necessity of off-device sample pretreatment. Off-device sample pretreatment varies widely, including simple dilution, mixing with reagents, centrifugation, pre-incubation, or nucleic acid (NA) extraction requiring multiple steps (*e.g.*, heating, washing, elution, *etc.*) (Tables S1–S3). Among the most common off-device pretreatments in clinical diagnostics, blood separation and NA extraction, numerous studies have reported their successful on-device integration. Readers are referred to related reviews for further details.^{10,18} Even if it is difficult to integrate sample pretreatment, selection of appropriate off-device pretreatment methods is at least important to enhance user-friendliness. For example, while conventional NA extraction by means of commercial kits usually takes around 20 min and requires centrifugation, Zhang *et al.* adopted a simple thermal lysis method instead, which completes within 5 min and eliminates the need for centrifugation.²⁸ For these reasons and considering the ongoing efforts to on-device integration of sample pretreatment, we believe that fully integrated μ PADs eliminating needs for off-device sample pretreatment deserve greater attention.

The necessity of precise time control is summarized in Tables S1–S3. For assays involving only a single reaction step, precise time control can be avoided by signal readout at saturation, or immediately after sample application, the latter being mostly limited to electrochemical measurements. To determine the feasibility of such strategies, the investigation of reaction kinetics would be of high importance. However, this is often not sufficiently addressed in the literature. On the other hand, assays that unavoidably need precise time control can be broadly classified into two categories: in the first one, the signal evolves over time following a single- or multi-step reaction, requiring signal readout at a fixed time after sample application. The second category includes assays involving multiple user interventions at defined time intervals. The former type has greater potential for

adaptation to point-of-care testing (POCT), since automated signal acquisition systems can be implemented to eliminate the requirement for exact time control by the user.²⁹ In contrast, for the latter category, apart from automated reagent or buffer addition described in the following sections, integration of a built-in timer into μ PADs is the only practical way to enhance usability.^{30,31}

The most commonly reported external equipment for use with μ PADs is nowadays the smartphone, often combined with self-made controlled light boxes or 3D-printed attachments. Such setups are generally more user-friendly than scanners, RGB colour sensors, or benchtop fluorimeters. Readers are referred to a recent review summarizing advances in smartphone integration with μ PADs.³² On the other hand, some reports on colorimetric signal detection do not investigate the feasibility of naked-eye signal interpretation, although the shown figures indicate such possibility. To maximize the potential of instrument-free signal detection, the determination of visual detection limits (ideally evaluated by multiple observers) is of high importance.^{22,28,33} Apart from external equipment for signal detection, heaters or incubators are often involved, especially in NAT, as mentioned earlier (Table S2). Among these, Lee *et al.* reported an interesting approach using a power supply-free heating module based on the exothermic reaction of calcium oxide with water. That system achieves precise temperature control using a wax melting near the optimal temperature for isothermal amplification, thereby enhancing the usability in resource-limited areas.²⁴

To summarize the general progress in μ PAD development, assays targeting routine health checks or relying on simple reaction mechanisms have nearly reached true sample-in-answer-out functionality. In contrast, immunoassays and NAT, which require multiple operation steps or higher sensitivity, still demand further advancements before reaching that level of integration. The greatest remaining challenge lies in the necessity of off-device sample pretreatment. Most clinical validation testing has been conducted using serum or NA-extracted samples, rather than raw biological fluids such as whole blood. While such off-device sample pretreatment may be acceptable for μ PAD applications in small clinics equipped with compact centrifuges or incubators, it remains impractical for bedside diagnostics, at-home testing, or use in resource-limited settings. Accordingly, the development of fully integrated sample-in-answer-out μ PADs capable of integrating on-device sample pretreatment is expected to remain a key research trend. However, when assessing whether μ PADs described by authors as “fully integrated devices” truly live up to that designation, it is important to simultaneously look at multiple parameters summarized in Tables S1–S3. For example, an excellent long-term storage stability might be reported for a μ PAD, but a closer look reveals the omission of pre-deposition of sensitive reagents needed in the assay. In other cases, a significant reduction in μ PAD operation steps might be reported but accompanied by extensive off-device

sample pretreatment. Moreover, for cases reporting a comparable number of device operation steps, whether precise time control is required can greatly affect the overall complexity of the assay. In other words, we believe the parameters listed in Tables 1–3 and S1–S3 are useful to evaluate and effectively judge user-friendliness of μ PADs.

Improvement in performance-oriented parameters

In the following sections, we describe fundamental improvements in performance-oriented parameters of general μ PADs, including sensitivity, precision, rapidity, and long-term storage stability. Although the examples introduced below do not exclusively target diagnostic applications, the demonstrated proof-of-concept approaches are readily applicable to diagnostic applications, as they primarily focus on μ PAD design itself rather than on specific reaction mechanisms or specific target analytes.

Sensitivity and precision

The detection ranges achievable with various analytical methods for μ PADs, including colorimetric, fluorescence, electrochemical, and chemiluminescent approaches, were discussed in detail in our 2017 review.¹⁰ In general, improving sensitivity can be approached through multiple assay design strategies. For immunoassay formats, for example, enhancing washing efficiency to reduce background noise and applying enzyme-mediated signal amplification are both effective means of increasing sensitivity.³⁴ However, these improvements typically require additional operational steps or sequential reagent addition, which in turn compromise user-friendliness and can limit applicability in resource-limited or self-testing environments. In this context, considerable effort has been devoted to incorporating automated fluid control systems into μ PADs, enabling sequential delivery of reagents or buffers with minimal user intervention. This technology is expected to facilitate the translation of highly sensitive laboratory-based clinical assays that require multiple operational steps into bedside or at-home point-of-care diagnostic applications. Even in 2017, a handful of approaches aimed at simplifying these operations have already been reported,^{35–37} but since then, a broader variety of novel strategies has emerged, as introduced in the following subsections.

First, it is worth noting that the early concepts already discussed in our previous review, such as maze-like channel layouts,³⁸ sucrose-based dissolvable barriers,³⁹ and origami-type folding valves,⁴⁰ have continued to be used in later years, either with further optimization or by introducing alternative or mixed sugars to refine liquid flow delay profiles. Approaches requiring user intervention and/or external equipment have also appeared in recent years, including sliding or movable reagent pads,^{41,42} manually rotatable platforms,³¹ centrifugal paper-fluidic devices,⁴³



thermally actuated shape-memory-polymer valves,²¹ and manually controlled hydrophilic bridges.⁴⁴ While these methods enable precise timing control, they still depend on user intervention or additional hardware, thereby limiting their applicability in fully autonomous point-of-care devices.

A growing number of passive strategies not requiring user intervention has been developed, enabling single-step assays with self-sequenced liquid delivery. These include mechanisms based on aqueous two-phase systems,⁴⁵ hydrogel- or swelling polymer-based valves,^{46,47} and mechanical delay elements such as accordion-folded paper.⁴⁸ However, these approaches can suffer from certain limitations: their applicability may be restricted to specific assay types, the reproducibility of delay times is sometimes relatively low, and the increased fluid viscosity resulting from dissolved valving materials may affect downstream fluidic transport and enzymatic reactions. On the other hand, Park *et al.* reported a mechanical compression-based delay method in 2017, where deforming part of a paper channel by applying pressure slowed the fluid flow, with delays tuneable up to approximately 3.5 minutes depending on compression strength (Fig. 1a).⁴⁹ This approach was then integrated in a sequential ELISA (enzyme-linked immunosorbent assay) workflow, illustrating its utility for immunoassays without requiring additional chemical barriers. Subsequently, Strong *et al.* developed a wax-printed time-delay channel method by printing wax from both sides of the paper substrate (Fig. 1b).⁵⁰ This design partially sealed the channel and increased capillary flow resistance, achieving precise liquid flow delays of up to around 800 seconds by changing the coverage percentage of wax deposited on the channel (shown as yellow areas in Fig. 1b, top). The technique was applied to multi-step biochemical assays, demonstrating that wax patterning can serve as a low-cost and reproducible timing mechanism in fully integrated devices. More recently, Lee *et al.* introduced a delamination timer concept by printing a hydrophobic ink with lower water resistance than that used to fabricate the main channels.⁵¹ Upon wetting, this interface gradually separated from an adhesive film, thereby opening the flow path (Fig. 1c, top). By adjusting the printed barrier width and the number of barriers, delays ranging from 30 seconds to over 18 hours were achieved. This timing mechanism was successfully integrated into automated ELISA and DNA purification workflows, showcasing its versatility for both protein- and nucleic acid-based assays. In a very recent application of this system by Dai *et al.*, adjustments of the delamination ink deposition widths (Fig. 1c, bottom left) enabled control of flow delays between 150 s and 900 s (Fig. 1c, bottom right).⁵² In addition to these systems, several flow-control strategies have been reported by accelerating flow speed through gap-controlled dual-layer paper designs⁵³ or hollow-channel structures embedded within paper.⁵⁴ These concepts will be described in greater detail in the following section. Along with it, controlling the microfluidic channel length provides another means to realize sequential reagent delivery. Chien

et al. reported a one-step vertical flow paper-based immunoassay with on-device signal amplification, in which pre-deposition of reagents combined with control of channel lengths enabled a fully automated reaction without any user intervention.²² Specifically, they achieved around 5 min delay of amplification reagent delivery (blue arrows in Fig. 1d) after initial sample flow (red arrows) through design of the total channel length in 3D- μ PADs.

Overall, it should be noted that automatic time-delay and sequential reagent delivery strategies that do not rely on dissolvable materials tend to offer higher reproducibility compared with sugar- or polymer-based approaches. Improvements in reproducibility for assays requiring sequential reagent delivery are important to enhance the potential of μ PADs to bridge the gap between highly sensitive, multistep lab-based clinical assays and real-world point-of-care diagnostic applications. However, to date, most such developments have been limited to lateral flow assay formats, whereas in vertical flow assays, delay control is still typically achieved using sugars or polymers,^{25,39} or by employing origami-type devices^{30,55–60} that require user intervention. Therefore, this area would profit from further development to extend the applicability of highly reproducible delay mechanisms free of any valving materials to vertical flow assay platforms.

Rapidity

In paper-based microfluidics, the speed of fluid transport driven by capillary action is strongly influenced by the pore size of the paper substrate, as described by the classical Washburn equation.⁶¹ While slower transport rates can be advantageous in certain contexts, for example enabling devices with distance-based readout that rely on time-dependent flow⁶² or facilitating antigen–antibody binding requiring a certain interaction time,⁶³ they have generally been regarded as a limiting factor for achieving rapid diagnostics. Accelerating liquid flow not only shortens assay turnaround time but can also enhance analytical performance by reducing diffusion-driven dispersion of analytes during transit. One of the most prominent approaches involves introducing a gap between two layers, at least one of them being paper. This concept, originally introduced in 2012 by Jahanshahi-Anbuhi *et al.*,⁶⁴ has been further investigated by other research groups even prior to 2017.^{65,66} In 2018, Channon *et al.* demonstrated that introducing an optimized height of interlayer gap between two paper layers in taped devices increased the flow rate to 1.56 cm s⁻¹, which is higher by around 145-fold in comparison to the classical liquid wicking within a single paper layer following the Washburn behaviour (Fig. 2a).⁵³ This strategy was subsequently applied to enhanced electrochemical flow injection analysis of cadmium ions and virus particles.^{53,67} This method has since been used in various μ PAD applications, continuing to be reported in studies up to the present.^{68–74}






Fig. 1 Examples of passive strategies enabling automated sequential reagent delivery on μ PADs by creation of liquid flow delays: a) top left: schematic of a 3D paper-based microfluidic device for measuring liquid flow delay time induced by compression of paper; top right: relationship between applied pressure and time at which blue color appeared in the outlet; bottom: operation principle for the measurement of flow delayed. Adapted from Park *et al.*⁴⁹ Copyright 2017, with permission from Elsevier. b) Top: Schematic representation of wax deposition on μ PADs; black wax was used to define the border of the hydrophilic flow channel, while yellow wax was applied for fluid time delay creation (indicated as % coverage of the paper channel); bottom: wicking distance over time depending on coverage percentage of yellow wax on channel. Adapted from Strong *et al.*⁵⁰ published by MDPI. c) Schematic illustration of the timer mechanism and fluid flow process in channels with timers opening sequentially from left to right, and the relationship between timer widths and corresponding delays. Adapted from Dai *et al.*⁵² Copyright 2026, with permission from Elsevier. d) Folding diagram of μ PAD and flow process between 0 to 10 min displays the different assay stages from sample injection, detection, and signal amplification, with the reagent flow at various time points indicated; red arrows: sample detection flow; blue arrows: signal enhancement reagent flow. Adapted from Chien *et al.*²² Copyright 2025, with permission from Elsevier.

More recently, there has been a noticeable shift toward hybrid device architectures that do not rely solely on paper for fluid transport. Instead, paper is strategically positioned as a reagent chamber or detection zone, while fluid transport is handled by alternative materials with inherently higher wicking or flow rates. Examples include polymer films,⁷⁵ polydimethylsiloxane (PDMS) microchannels,⁷⁶ cellophane,⁷⁷ and 3D-printed substrates,⁷⁸ each integrated to form continuous flow pathways that bypass the inherent speed limitations of cellulose-based materials. In the following, some examples not necessarily related to diagnostic applications are discussed, since they represent approaches that are potentially applicable to that field. Arun *et al.* combined PDMS and paper channels, achieving a significant enhancement of fluid transport rate and mixing

performance.⁷⁶ Aryal *et al.* reported a capillary-driven PAD combined with transparency film for heavy metal detection in 2023 (Fig. 2b).⁷⁵ While conventional μ PADs require minutes to deliver samples to the detection zone, the developed device took only 8 s until colour signals appeared, pointing to a flow rate of roughly 0.3 cm s^{-1} . This velocity is about 30-fold higher than the classical liquid wicking process within a single paper layer. Although designed for environmental monitoring, the mechanism itself could readily be adapted for diagnostic purposes.^{79–81} Later, Macleod Briongos *et al.* reported a 59–74% improvement in liquid flow rate by the fabrication of laser-cut grooves on paper.⁸² Lastly, Park *et al.* fabricated flow channels on a paper substrate using a digital light processing (DLP) 3D printer.⁷⁸ While quantitative flow speed data was not






Fig. 2 Selected approaches towards μ PADs with increased sample liquid flow rates: a) illustration of straight channel multilayer μ PAD with a gap defined by the thickness of double-sided tape (iii) in between two hydrophobic wax-patterned paper layers, and effect of channel height on flow rate for horizontal and vertical 2-layer μ PAD. Adapted from Channon *et al.*⁵³ b) Illustration of assembly of device made from paper and transparency film, and its operation, and effect of channel width on time for sample to reach detection zone. Adapted with permission from Aryal *et al.*⁷⁵ Copyright 2023 American Chemical Society.

provided, the assay time of the device with 3D printed channel was shorter than that of typical 2D μ PADs, which was attributed to an increase of fluid flow speed in the small channels embedded within the paper. Through such approaches combining paper with non-paper materials into single devices, researchers have demonstrated the feasibility of significantly reduced assay times, while retaining key advantages of paper, such as the low cost and biochemical compatibility. The examples highlighted in Fig. 2 demonstrate that designs to accelerate the liquid flow speed, including interlayer gaps and hybrid fluidic pathways, can simultaneously shorten assay time and improve analytical performance by limiting diffusion-driven analyte dispersion. These combined effects enhance the practicality of μ PADs for rapid and reliable diagnostic applications, particularly in point-of-care settings where both speed and accuracy are critical.

Long-term storage stability

Over the last few years, the storage stability of μ PADs has received greater attention than in the past, with many recent studies assessing device performance over storage periods of mostly one month (Tables 1–3). Notably, some reports that extended storage tests beyond one month observed significant declines in stability,^{26,38,83,84} highlighting the importance of truly long-term investigations. The longest storage durations among the analysed publications were 10 weeks, 12 weeks, and 3 months, which still fall short of

commercial requirements.^{44,85,86} However, such long-term studies present a fundamental challenge in academic settings, where publication timelines and the pressure for novelty often discourage a year-long or multi-year data collection. One potential solution is accelerated stability testing based on the Arrhenius equation.⁸⁷ By exposing the devices to a harsher than usually encountered environment (typically at elevated temperature), the equivalent of long-term storage can be simulated within a much shorter period. While this method is often used in the biosensor field,^{88,89} there are few reports adopting it to μ PADs. Yakoh's group recently introduced accelerated shelf-life testing for μ PADs by storing devices at 55 °C, thereby reducing the required testing period to approximately one-eighth of the normal duration. This approach provides a practical way for more efficient evaluation of long-term storage stability.^{90,91}

Looking at more details of the storage stability studies presented in Tables S1–S3, it is revealed that the thresholds used to define acceptable signal changes vary widely, typically ranging from 5% to 20%. Some reports do not even mention quantitative results, which makes it difficult to compare across different studies. To address this issue, we believe that as long as commonly accepted standards are not available, setting multiple threshold levels of acceptable signal change and indicating the corresponding storage stability for each of those would be the most practical approach. Furthermore, while most studies monitor the signal stability in the absence and presence of target analyte, some investigations use calibration plots covering a wide target analyte concentration



range.^{57,92} The latter approach is more effective for assessing device behaviour over storage time, especially in the lower analyte concentration range, where performance degradation may have a stronger negative impact.

Regarding strategies to extend μ PAD storage stability, most remain consistent with those described in our 2017 review. Namely, incorporating stabilizing agents such as small molecules,⁹³ proteins,^{94,95} polymers,^{26,96} sugars,⁹⁷ or micro/nanoparticles²⁷ into the device matrix. Particular attention continues to be paid to the stability of enzymes, which are often the most degradation-prone components in μ PAD assays.⁹⁸ In this context, the use of nanozymes as enzyme mimics has emerged as a noteworthy trend.^{99,100} These nanomaterial-based catalysts generally exhibit superior thermal stability and prolonged activity, potentially alleviating the shelf-life bottleneck. While some studies confirmed the long-term storage stability of nanozyme-assisted PADs for more than two months,^{101,102} others reported stability for about 1 month,^{103,104} with certain nanozymes retaining activity for as little as 2–3 weeks.^{105–107} Since there has been no report directly comparing long-term storage stability of natural enzymes and nanozymes on paper substrates, more comprehensive research in this direction is needed in the future. It should also be noted that the use of nanozymes involves a trade-off in target specificity, which could compromise analytical accuracy unless compensated by further innovations in nanozyme design. Thus, nanozyme-assisted PADs are sometimes combined with natural enzymes such as glucose oxidase.¹⁰⁸ However, by combining nanozymes and natural enzymes in a single PAD, the advantages of the former in terms of device storage stability are possibly sacrificed. Meaningful progress in this field will depend not only on assay engineering but also on advancements in the broader field of nanozyme chemistry.

As summarized earlier, long-term storage stability testing is still often overlooked even in simple assays and is further complicated by inconsistencies in the evaluation criteria. Hence, it is important to remain critical of these aspects when considering the real-world applicability of μ PADs.

Simplified signal interpretation beyond purely qualitative readouts

As already mentioned in the introduction, early μ PADs primarily relied on benchtop sized equipment and computer software for quantitative data interpretation, or on qualitative binary visual indications, such as the simple presence or absence of a coloured line. The former offered limited accessibility for POCT, while the latter were vulnerable to user subjectivity, particularly near clinically relevant threshold concentration values. In our previous review, we already introduced several concepts for semi-quantitative assays, which do not sacrifice user-friendliness, including counting-based,¹⁰⁹ timing-based,¹¹⁰ distance-based,⁶² and text-based signal readout formats.¹¹¹ Since 2017, however, a

range of new approaches has been reported, further advancing this field.

One of the most widely explored concepts has been distance-based formats, in which the migration length of a coloured front in a paperfluidic channel correlates with analyte concentration. Lee *et al.* converted the originally straight channel design to angular readouts,¹¹² thereby enabling more compact device layouts while retaining the concentration resolution. Subsequently, Teprek *et al.* and Khachornsakkul *et al.* introduced counting-based schemes in which discrete reaction spots along the channel sequentially change colour as the sample liquid progresses in vertical and lateral flow configurations, respectively (Fig. 3a and b).^{113,114} Multiple paper layers in an origami-type device have been modified with reagents, for example for the titrimetric determination of Ca^{2+} levels. Sample liquid passing vertically through the device, thereby reacted with the pre-deposited reagents on each circular reaction zone, resulting in depletion of the target analyte and hence, changes in the number of spots showing a colorimetric reaction (Fig. 3a). In an alternative design based on a similar reaction principle, results are interpreted by counting colored zones in a circular lateral flow arrangement. Also building upon the distance-based readout concept, others have incorporated machine-readable patterns such as for example QR codes,¹¹⁵ enabling smartphones to decode the reaction pattern and translate it into concentration data (Fig. 3c). Multiple QR codes composed of colorimetric indicators were placed in series into a paperfluidic channel. In absence of analyte, all QR codes are hidden, but an increasing number becomes readable with increasing analyte concentrations. Although the latter study targeted heavy metal ions for proof-of-concept, the same approach is also applicable to diagnostic assays. More recently, Manmana *et al.* introduced a system converting a distance-based concept into a 1D barcode-based signal readout¹¹⁶ for a semi-quantitative glucose assay in artificial urine matrix (Fig. 3d).¹¹⁷ The barcode-based readout offers the advantage of single-step result interpretation from a single code, compared to the QR code-based system requiring the scanning of multiple QR codes to obtain semi-quantitative results. Only specifically designed QR code patterns offer the possibility for a semi-quantitative single QR code assay.¹¹⁸ Both QR- and 1D barcode-based signalling strategies offer clear advantages in terms of simplifying data digitization and storage, features not that readily achieved with more conventional readout methods.

In parallel, transparent film-supported strategies have emerged as an alternative means of interpreting results of colorimetric assays. In 2017, Yamada *et al.* reported a text-displaying colorimetric PAD, in which chemical reactions trigger colour development of indicators inkjet-deposited onto paper in the form of text. When overlaid with a transparent film featuring coloured zones of varying colour shades and intensities, the underlying text symbols (*e.g.*, “trace”, “1+”, “2+”) become readable only when their colour intensity surpasses a threshold corresponding to a specific






Fig. 3 Examples of μ PADs enabling naked eye (semi-)quantitative signal readout: a) illustration of a folded origami-type μ PAD with sample application, and standard colour scale used for interpretation of experimental results on μ PAD for end point detection in titrimetric analysis; increasing number of purple spots indicates higher target analyte levels (e.g. Ca^{2+}). Adapted from Tepak *et al.*¹¹³ Copyright 2020, with permission from Elsevier. b) Illustration of a device and method to interpret results by counting colored zones in a circular lateral flow arrangement. Adapted with permission from Khachornsakul *et al.*¹¹⁴ Copyright 2022 American Chemical Society. c) Photograph of QR code array PADs relying on the distance-based signalling mechanism after application of various Cu^{2+} concentrations. Reproduced from Katoh *et al.*¹¹⁵ d) Schematic illustration explaining the principle of semi-quantitative 1D barcode readout PADs; red arrows in the right panel indicate bar positions that change from normal to wide state with increasing analyte concentration, thereby converting the distance-based concept into a changing barcode signals. e) Schematic showing the working principle of a text-displaying device; overlaying a transparent film with screening colour on a paper layer with inkjet-deposited reagents for colorimetric protein detection (human serum albumin) results in the readability of text depending on the urinary albumin level. Adapted from Yamada *et al.*³³ Copyright 2017 American Chemical Society. f) Schematic showing the working principle of a “dip-and-read” distance-based detection method; overlaying a transparent film with colour gradient on a paper layer with a colorimetric reagent deposited in the form of a line results in a target analyte concentration-dependent change in the visible line length. Adapted from Yamada *et al.*¹¹⁹ g) Photographs of origami- μ PAD, schematic cross-sectional view of multilayer origami-type traffic light μ PAD and illustration of varying liquid flow paths depending on a hydrogen peroxide-responsive hydrophobic to hydrophilic phase-switching reagent (hydrophobic wall) resulting in H_2O_2 concentration-dependent traffic light colour display. Adapted from Ohta *et al.*¹²⁰

urinary albumin concentration (Fig. 3e).³³ Later on, in 2018, a “dip-and-read” distance-based detection method was developed by modifying the transparent film overlay concept. Using a film with a colour gradient, a line of colorimetric indicator printed on a paper substrate becomes visible to the

naked eye only in regions where its colour exceeds that of the overlaid film (Fig. 3f).¹¹⁹ Although so far only demonstrated for Ni quantification, this method is expected to be equally applicable to diagnostic assays. This “quasi distance-based” readout approach offers advantages over most conventional



distance-based assays in terms of speed and independence from the applied sample volume. Because the entire PAD is dipped into the sample liquid, rather than relying on the application of a fixed sample volume to an inlet area, it is not necessary to wait for the completion of fluid wicking through the device. However, the method is more likely to be affected by ambient light conditions.

Finally, several additional innovations exploit microchannel engineering to encode concentration information. Ohta *et al.* reported a multi-layer origami traffic light μ PAD for semi-quantitative glucose detection in artificial urine, achieved by varying liquid flow paths, channel geometry and width, and the concentration of a hydrogen peroxide-responsive hydrophobic to hydrophilic phase-switching material (Fig. 3g).¹²⁰ While earlier traffic light type μ PADs relied on smartphones for augmented reality-based result display¹²¹ or fluorescence-based signal output,¹²² the origami device enabled naked-eye readout *via* coloured spots composed of food dyes that maintain a stable time-independent colour appearance resistant to fading, in contrast to many chromogenic indicators. The approaches shown in Fig. 3 demonstrate how advances in semi-quantitative visual and encoded signal outputs can transform μ PAD readouts beyond purely qualitative analysis. Such improvements in interpretability and consistency are crucial for diagnostic applications in resource-limited settings, thereby strengthening the applicability of μ PADs for real-world point-of-care testing.

On the other hand, smartphone-based signal detection approaches represent one of the most important strategies for enabling target quantification. They have already been explored prior to 2017, as discussed in our previous review. However, many early smartphone readout methods suffered from the influence of external light variability, requiring dedicated light sources or enclosed imaging boxes to ensure consistent measurements.^{123,124} Chen *et al.* addressed this limitation by scattering the smartphone's built-in flash to achieve uniform illumination (Fig. 4a).¹²⁵ Fan *et al.* mitigated the issue by adapting image processing algorithms to correct for ambient light fluctuations (Fig. 4b).⁹² Alongside these hardware- and software-based improvements, there has been a rise in studies explicitly validating smartphone compatibility as part of μ PAD design, positioning mobile phone-based detection as a key enabler for achieving true POCT functionality.^{13,32}

Signal detection methods and analytical techniques recently integrated into μ PADs

While much of the development in μ PADs since 2017 has focused on refining existing methodologies, the broader field of analytical chemistry has also witnessed the emergence of entirely new technologies with transformative potential. Several of these innovations originally developed without




Fig. 4 Examples of approaches mitigating the influence of external light variability in smartphone-assisted μ PAD signal readout: a) photographs of 3D printed assembled imaging box with smartphone and illustration of light diffusion upon scattering of the smartphone's built-in flash to achieve uniform illumination for readout of μ PADs. Adapted from Chen *et al.*¹²⁵ Copyright 2019, with permission from Elsevier. b) Principle of colour correction using a standard colour bar: automatic recognition of colour bar region, measurement of RGB colour intensities, and reconstruction of image. Adapted with permission from Fan *et al.*⁹² Copyright 2022 American Chemical Society.

μ PADs in mind have begun to find their way into paper-based platforms, enabling capabilities that were previously unattainable in such simple formats. Integration efforts remain relatively limited in number, but their trajectory suggests a growing interest in leveraging these advances for portable, low-cost diagnostics. In this section, we highlight three representative areas where analytical technologies have newly intersected with μ PAD research: 1. detection techniques involving surface-enhanced Raman scattering (SERS)^{126,127} or bioluminescence¹²⁸ that push detection sensitivity towards low analyte amounts, 2. techniques represented by CRISPR-based assays,^{129,130} and 3. machine learning (ML)-assisted image analysis and data interpretation, that enhance accuracy and selectivity.^{131,132}

These examples illustrate how the convergence of emerging analytical tools with μ PADs could redefine the boundaries of point-of-care testing in the coming years.

Surface-enhanced Raman scattering (SERS)

SERS is a highly sensitive detection technique that enhances the weak Raman scattering of molecules adsorbed onto corrugated metallic surfaces through localized surface plasmon resonance.^{126,127} This technique has enabled ultrasensitive, label-free molecular detection through distinct



peaks in Raman spectra representing “fingerprints” of target analytes. Raman signals are enhanced by factors up to 10^8 or even larger,¹³³ when target molecules are located within hot spots, formed through metallic nanostructures on various solid substrates. Owing to this feature, SERS has gained considerable attraction in the analytical chemistry field in the 2000s, particularly for applications that demand high sensitivity, such as in biomedicine, environmental monitoring, and chemical reaction monitoring.¹³⁴ The combination of SERS with paper substrates has attracted interest since the 2010s,^{135,136} largely due to the inherent advantages of paper materials, including biocompatibility, physical flexibility, passive fluid transport through capillary action, low cost, and portability as summarized in several review articles devoted to this specific topic.^{137,138}

However, most reports adopting paper as a SERS substrate are not directly related to diagnostics and just marginally mention such application potential as a future perspective, with the exception of some LFIAs. A key bottleneck lies in the detection system itself. For example, Lim *et al.*¹³⁹ and Mabbott *et al.*¹⁴⁰ reported paper-based SERS for the detection of acute myocardial infarction biomarkers and a microRNA associated with myocardial infarction. The former one achieved multi-target detection through a multi-channel design fabricated on a single paper (Fig. 5a), and the latter one successfully simplified the assay procedure by integrating a multi-step reaction assay into a multi-layered vertical μ PAD (Fig. 5b). Both approaches use gold nanoparticles modified with Raman reporter molecules and either capture antibodies or DNA oligomers complementary to the target RNA. On the other hand, their work still relied on laboratory-scale SERS detecting modules. Therefore, paper-based SERS approaches must be developed along with the miniaturization of Raman spectrometers including laser source, detectors, and optical components, before achieving true POCT capability.¹⁴¹ While there are many reports devoted to the development of portable Raman spectrometers, including those compatible with smartphones, the trade-off between instrument size and analytical sensitivity remains a significant challenge.¹⁴¹ Moreover, publications describing the successful integration of paper-based SERS and portable spectrometers, as for example reported by Zeng and co-workers, are currently mostly limited to typical model targets including rhodamine 6G, malachite green and crystal violet with their distinctive C=N spectral features (Fig. 5c).^{142,143} Considering this fact, as well as the still relatively high costs of portable Raman spectrometers, more work is required looking at both aspects of potential practical application to meaningful analytical targets and portable and low-cost, but sensitive Raman signal detecting instruments.

Bioluminescence

Bioluminescence (BL) is a subcategory of chemiluminescence, with light emission produced by an oxidation reaction involving an enzyme (luciferase) and its




Fig. 5 Examples of μ PAD signal readout approaches relying on surface-enhanced Raman scattering (SERS): a) schematic illustration of multiplexed μ PAD with signal acquisition by SERS for detection of acute myocardial infarction biomarkers. Adapted from Lim *et al.*¹³⁹ Copyright 2020, with permission from Elsevier. b) Illustration of detection method for microRNA miR-29a in a 3D μ PAD and representative images of sample readout using both colorimetric and SERS methods for samples containing miR-29a (+ve) and samples without miR-29a (-ve). Adapted from Mabbott *et al.*¹⁴⁰ c) Schematic illustration of sample application on paper substrate and detection using a miniaturised smartphone-based Raman analyser. Adapted with permission from Zeng *et al.*¹⁴² Copyright 2019 American Chemical Society.

substrate (luciferin) in living organisms. Compared to other optical detection techniques applied to μ PADs relying on colorimetric or fluorescence signals, chemiluminescence and BL have the advantage of achieving superior signal-to-noise ratios due to the nearly zero background signal. At the same time, they eliminate interference caused by environmental light conditions as in case of colorimetric approaches, or the necessity of external light sources for fluorescence-based detection. BL is particularly attractive due to the enzyme reaction resulting in generally higher quantum yields compared with chemiluminescent systems, allowing ultrasensitive target detection down to attomole levels.¹²⁸

While BL-based analytical assays have been reported for decades in laboratory settings, their application to paper-based analytical devices (PADs) started more recently in the late 2010s. One of the earliest reports appeared in 2014 by



the Johnsson group, where a BL-based reaction was performed on a filter paper substrate with a 96-wellplate-like design.¹⁴⁴ Their system relies on ratiometric BL sensor molecules referred to as luciferase-based indicators of drugs (LUCIDs), enabling the detection of several types of drugs by monitoring changes in the emission colour caused by a bioluminescence resonance energy transfer (BRET) process. However, this approach was still remote from a POCT applicable system, since all reagents were applied during the assay, with the paper platform solely acting as a replacement for plastic microwell plates for the purpose of reducing sample and reagent volumes. Several years later, the same group demonstrated a related BRET-based assay with sensing proteins lyophilized on paper substrates,¹⁴⁵ a first step towards reducing the burden of reagent handling by the assay user. Subsequently, Tenda *et al.* reported fully-integrated BRET-based μ PADs using a different type of BL molecular sensor named LUMABS (luminescent antibody sensor) (Fig. 6a).²³ By pre-deposition of both LUMABS and its substrate furimazine on spatially separated paper layers, simultaneous detection of antibodies against HIV, hemagglutinin, and dengue virus was achieved by the application of a single drop of whole blood and subsequent acquisition of a photograph in the dark, without any reagent handling. However, when compared to other paper-based immunoassays, the achieved limit of detection in the nanomolar order is relatively high (Table 1). A major advantage of all BRET-based approaches is that BL signals are recorded as changes in emission colour, rather than the highly time-dependent BL emission intensity. The latter necessitates stricter control over signal readout timing.

Since then, a growing number of BL-based μ PADs has been reported. However, the greatest challenge in applying BL to μ PADs lies in the limited stability of bioluminescent substrates under ambient and even refrigerated conditions.^{95,146} As a consequence, these substrates are often not pre-deposited on the μ PAD but added along with or after sample application, limiting user-friendliness.^{86,147–149} In some cases, long-term storage stability has not been adequately investigated.¹⁵⁰ BL bacteria-based assays are superior in terms of stability, but their assay mechanism might limit analyte selectivity, since it commonly relies on the inhibition of bacterial enzymatic reactions by the target molecules.^{151,152} While not using paper as the assay platform, Kurita *et al.* reported a BL substrate named Hulumino1, a coelenterazine analogue (Fig. 6b, top).¹⁵³ They targeted human serum albumin in serum samples, which behaves as a luciferase catalysing the oxidation of Hulumino1 pre-deposited on a polyethylene strip in a dry film state, producing a corresponding BL signal (Fig. 6b, bottom). While BL intensity rapidly decreased to 68% when devices were left at room temperature overnight after fabrication, approximately 50% of the initial luminescence intensity was still retained after one month stored at room temperature due to the premature substrate oxidation being limited to the surface of the dry film. But given that for many reported BL-




Fig. 6 Paper- and polymer-based POCT devices with bioluminescence signal readout: a) schematic of the luminescent antibody sensor (LUMABS) working principle, its integration into a multi-layer 3D- μ PAD, and its use for simultaneous detection of three different antibodies. Reproduced from Tenda *et al.*²³ b) Comparison of chemical structures of native luciferin coelenterazine with an imidazopyrazinone derivative (Hulumino1) used as human serum albumin (HSA)-responsive luciferin, and measurement procedure for serum HSA with Hulumino1 pre-deposited on polyethylene strip in a dry film state. Adapted from Kurita *et al.*¹⁵³ Copyright 2025, with permission from Elsevier.

based assay devices even storage under vacuum condition could not achieve long-term stability under ambient conditions,¹⁵⁴ chemical encapsulation or molecular structure modification of BL substrates are expected to offer more promising solutions.¹⁵⁵ However, it should be noted that extension of storage stability often comes at the expense of assay sensitivity, since increased resistance to air oxidation potentially reduces the reactivity of the BL substrates. Overall, continued efforts in this direction are required to lead to fully integrated μ PADs with high long-term storage stability under ambient conditions.

CRISPR-based assay techniques

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) protein



systems initially attracted attention in the field of gene editing,¹⁵⁶ with their applications in analytical chemistry emerging in the late 2010s. CRISPR/Cas systems are classified into several subtypes according to their nucleic acid targeting properties, among which Cas9, Cas12, and Cas13 are most widely used.^{157,158} Common to all systems, a ribonucleoprotein (RNP) complex consisting of a Cas protein and a programmable guide RNA referred to as CRISPR RNA (crRNA), recognizes a specific nucleic acid sequence, after which the RNP complex becomes activated. Owing to their simple design, high specificity capable of distinguishing single-nucleotide mismatches, and the ability of signal amplification through *trans*-cleavage turn-over reactions (limited to Cas12 and Cas13), CRISPR-based assay techniques have been widely investigated up to now.

In the classical Cas9 system, the RNP complex targets double-stranded DNA (dsDNA) and cleaves it through the so-called *cis*-cleavage reaction. In 2016, Pardee *et al.* reported a Nucleic Acid Sequence-Based Amplification (NASBA)-CRISPR cleavage assay named NASBACC for Zika virus detection. In this system, isothermal nucleic acid amplification following reverse transcription of isolated Zika RNA, combined with the sequence-specific nuclease activity of CRISPR/Cas9, enabled discrimination of viral strains with single-base resolution.¹⁵⁹ They further demonstrated the feasibility of freeze-drying NASBACC reagents on circular-shaped paper discs, suggesting the applicability of this approach on paper-based assay platforms. On the other hand, the Cas13 system targets RNA, where the RNP performs *cis*-cleavage of the target RNA, followed by collateral indiscriminate cleavage of surrounding RNA molecules, a process referred to as

trans-cleavage reaction. The first Cas13-assisted assay was reported by Gootenberg *et al.* in 2017, termed Specific High-Sensitivity Enzymatic Reporter UNLOCKing (SHERLOCK).¹²⁹ By using a quenched fluorescent RNA reporter, the *trans*-cleavage activity of Cas13 triggered by RNA that was amplified through reverse-transcribed recombinase polymerase amplification (RPA) followed by T7 transcription was transduced into a fluorescence signal. This enabled the successful detection of specific strains of Zika and dengue virus, discrimination of pathogenic bacteria, as well as genotyping of human DNA, and identification of mutations in cell-free tumour DNA. Importantly, they also demonstrated the feasibility of freeze-drying SHERLOCK reagents on paper discs. Similarly, in the Cas12 system, the RNP complex targets and cleaves dsDNA, followed by collateral *trans*-cleavage of surrounding single-stranded DNA (ssDNA). In 2018, Chen *et al.* reported a Cas12a-based assay combined with RPA for the detection of human papillomavirus in patient samples.¹³⁰ Their assay method became known as DNA endonuclease-targeted CRISPR *trans* reporter (DETECTR). The detection mechanism closely resembles that of SHERLOCK, except that a quenched fluorescent ssDNA reporter is used instead of an RNA reporter. Subsequently, both SHERLOCK and DETECTR were integrated with paper-based lateral flow assays in 2018 and 2020, respectively.^{160–162} Based on this history of CRISPR-based diagnostics, further integration with paper platforms is expected to offer strong potential for POCT applications.

It is therefore no surprise that such integration has increasingly progressed. Since comprehensive reviews on this topic have been published recently,^{163,164} we here focus on




Fig. 7 Examples of μ PADs relying on CRISPR-based assay techniques: a) schematic of the stackable μ PAD design for operation with probe ssDNA-crosslinked CRISPR-responsive hydrogels for electrical readout, and SEM images of paperfluidic channels in the absence (top) and presence (bottom) of target dsDNA. From English *et al.*¹⁷¹ Adapted with permission from AAAS. b) Schematic of the sensor components of a face-mask-integrated SARS-CoV-2 wearable diagnostic μ PAD and key steps of the freeze-dried reactions, each separated by a poly(vinyl alcohol) (PVA) time delay. Nguyen *et al.*²⁵ Springer Nature, 2021, adapted with permission from SNCS. c) Design of a paper-based origami immunoassay device with pre-deposited reagents on multiple pads, and assay procedure. Adapted with permission from Suzuki *et al.*⁵⁷ Copyright 2025 American Chemical Society.



highlighting the crucial and critical aspects. While many μ PAD implementations currently employ CRISPR primarily at the signal detection stage,^{165–170} there is a growing trend toward fully integrated devices in which sample preparation, amplification, and CRISPR-mediated detection occur within a single paper-based platform, as described in an earlier section. A CRISPR-based μ PAD going beyond simple paper discs was first reported by English and Soenksen *et al.* in 2019 for the detection of Ebola ssRNA (Fig. 7a).¹⁷¹ The assay mechanism relies on viscosity changes in an ssDNA-crosslinked hydrogel in response to Cas12a-mediated *trans*-cleavage. The assay was carried out by adding a pre-incubated Cas12a RNP mixture together with RT-RPA-amplified nucleic acid and the DNA hydrogel on different paper layers. The resulting signal is obtained from dye flow in the bottom paper channel. The first fully integrated CRISPR-based μ PAD was reported by Nguyen and Soenksen *et al.* in 2021 (Fig. 7b).²⁵ Integration of sample collection, lysis, isothermal nucleic acid amplification, a SHERLOCK reaction zone, and a lateral flow strip minimized user-intervention, limited to just pushing an activation button to initiate fluid flow and subsequently reading the result by the naked eye. Furthermore, CRISPR-based diagnostics are not limited to nucleic acid detection, but also applicable to small molecules or metal ion targets by use of aptamers or antibodies through ELISA-like formats. Suzuki *et al.* reported a CRISPR-assisted origami paper-based ELISA for the detection of hepatitis B virus surface antigen in whole blood in 2025 (Fig. 7c).⁵⁷ The Cas12a system was used for signal amplification, in combination with DNA network-labelled antibodies initiating *trans*-cleavage of an ssDNA fluorescent reporter, resulting in higher sensitivity than conventional HRP-labelled ELISA. Moreover, by integrating a blood separation membrane and all necessary reagents onto paper layers, required end-user operation was reduced to paper flap folding and adding buffer solutions.

However, aside from the publications mentioned above, to the best of our knowledge, there have been no further reports of fully integrated CRISPR/Cas-related μ PADs in the diagnostic field. This gap can be attributed to several factors: the use of paper limited to a substrate material for signal detection (as seen in SERS-based approaches),^{172,173} the requirement for off-device sample pretreatment⁵⁹ or off-device nucleic acid amplification,^{39,169,174} the need for user-handled CRISPR-related reagents,^{175,176} or the absence of validation with biofluid sample matrices.^{94,177} Since these techniques are ongoingly developed, truly “fully-integrated μ PADs” making use of CRISPR/Cas systems remain highly anticipated.

Artificial intelligence integration

The integration of artificial intelligence (AI) technologies such as machine learning (ML), neural networks (NN), and deep learning (DL) has begun playing an increasingly important role in advancing POCT, particularly given their

rapid development in recent years.¹³¹ Since the early 2020s, these technologies have been integrated with μ PADs primarily for the following purposes:

- Enhancement of sensitivity, accuracy, and selectivity.
- Reduction of assay time.
- Improvement of image capture in colorimetric approaches by minimizing ambient light interference.
- Mitigation of interference from complex biofluid sample matrices.
- Simplification of experimental optimization steps.

This field, especially the development of ML-assisted fully integrated μ PADs, has been mainly advanced by the Ozcan group. Here, we introduce some relevant publications and discuss how their approaches achieved the objective listed above.

Joung *et al.* reported a DL-assisted vertical-flow μ PAD for serological diagnosis of early-stage Lyme disease in 2020 (Fig. 8a).¹⁷⁸ The nitrocellulose sensing membrane incorporated 13 immuno-reaction spots with different capture antigens or antigen-epitope containing peptides, as well as negative and positive controls. Two types of 3D-printed top cases were used for the uniform distribution of applied serum samples to all sensing spots and to generate colour signals through embedded gold nanoparticles (AuNPs) conjugated to anti-human IgM or IgG antibodies. By selecting an optimal subset of detection antigens from the 13 spots through ML and using batch-specific standardization and threshold tuning, they achieved an area-under-the-curve (AUC), sensitivity, and specificity of 0.963, 96.3%, and 85.7%, respectively. In the same year, Ballard *et al.* reported a similarly structured μ PAD for C-reactive protein (hsCRP) testing.¹⁷⁹ The device featured 81 immunoreaction spots of different antigens with different concentrations, from which optimal subsets were selected through ML as well. As a result, they successfully quantified hsCRP with an expanded dynamic range. As demonstrated by the examples above, increasing the number of result parameters enhances the performance of ML-based analysis. In this regard, signal detection techniques producing large scan-based datasets, such as electrochemical or SERS measurements, are particularly useful for ML or DL to enhance assay accuracy.^{180,181} On the other hand, simplification of multi-analyte detecting assays using distinct reaction spots for each analyte is another strength of μ PADs. However, Goncharov *et al.* introduced a different approach utilizing non-specific colour changes from multiple sensing spots for the quantification of three biomarkers, myoglobin, creatine kinase-MB (CK-MB), and heart-type fatty acid binding protein (FABP) using DL (Fig. 8b).¹⁸² While multivariable linear regression models only yielded coefficients of determination <0.85 , neural networks improved these values to 0.92, 0.93, and 0.95 for myoglobin, CK-MB, and FABP, respectively. Similarly, in 2024, Eryilmaz *et al.* categorized COVID-19 immunity levels based on the IgG and IgM concentration levels.¹⁸³ Furthermore, Ghosh *et al.* achieved single-tier serodiagnosis of Lyme disease by a single DL classifier






Fig. 8 Examples of μ PAD approaches with artificial intelligence integration: a) illustration of 13-immuno-reaction spots occurring on the nitrocellulose sensing membrane of a multiplexed paper-based immunoassay device for Lyme disease, expanded diagram showing paper layers of the device with two types of top holder, and image processing and deep learning (DL)-based analysis of the multiplexed sensing membrane. Adapted with permission from Joung *et al.*¹⁷⁸ Copyright 2025 American Chemical Society. b) Overview of the multiplexed paper-based fluorescence vertical flow assay with multiple sensing spots, and neural network-based biomarker quantification of myoglobin, CK-MB and FABP. Adapted from Goncharov *et al.*¹⁸² c) Flow of image processing starting with image frame extraction from recorded video and architecture of the temporal sequence DL method in an ELISA-type μ PAD for cardiac troponin I (cTnI) detection. Adapted with permission from Zhu *et al.*¹⁸⁷ Copyright 2025 American Chemical Society. d) Neural network analysis-based correction of outlier clinical samples (yellow plots in left figure) caused by blood serum matrix interference in a chemiluminescence readout μ PAD for cTnI. Adapted from Han *et al.*¹⁹³

trained to simultaneously interpret the response to IgM and IgG antibodies.¹⁸⁴ In addition, inclusion of time-dependent colour change data into training datasets has been shown to contribute to sensitivity enhancement,¹⁸⁵ as well as to reduction of assay time without sacrificing the analytical performance (Fig. 8c).^{185–187}

Besides data interpretation, ML and DL approaches have also been used to assist the capture and processing of images in colorimetric assays. Mercan *et al.* used ML to automatically select the optimal analysis region of an image in cases where colorimetric reagents were heterogeneously distributed across a circular assay spot.¹⁸⁸ Compared with conventional colour threshold-based analysis, the ML-assisted approach was not affected by variations in seven different illumination conditions and four different smartphone models. Ning *et al.* further demonstrated result robustness not only to ambient light conditions but also to variations of image shooting angles.¹⁸⁹ Based on other similar reports,¹⁹⁰ these findings suggest that ML or DL-assisted μ PADs can enhance user-friendliness and reliability of smartphone-based assays.

As noted above, ML and DL have also been adopted to mitigate the interference from complex biofluid sample

matrices. Low *et al.* reported an ML-assisted μ PAD for accurate acute early diagnosis and prognosis of myocardial infarction.¹⁹¹ After evaluating eleven machine-learning algorithms, they achieved an area under the receiver operating curves (AUROC) of 0.97 ± 0.018 for all possible classification thresholds. Similarly, Jang *et al.* reported DL-assisted μ PADs integrated with field-effect transistors (FET) for cholesterol testing.¹⁹² In this system, cholesterol oxidase reacts with cholesterol to generate hydrogen peroxide, which modulates the FET's threshold voltage (ΔV_{th}). While relying on ΔV_{th} alone yielded a coefficient of determination of 0.81, the ML-integrated approach after training with optimal subset of specific range of time and gate voltage achieved high precision ($CV < 6.46\%$) and reasonable correlation ($r^2 > 0.976$) compared against results obtained from a certified laboratory. In another example, Han *et al.* focused on a small number of outlier clinical serum samples in cardiac troponin I detection using chemiluminescence (CL)-based vertical-flow μ PADs with a sandwich immunoassay format.¹⁹³ Three samples deviated significantly from the calibration curve based on normalized CL intensity (Fig. 8d). These deviations were attributed to serum matrix



interference, which was effectively corrected by neural network-based analysis.

On the other hand, integrating ML or DL with μ PADs resulted in the identification of unique features. Ning *et al.* noticed that including reagent batch IDs and fabrication batch IDs as input features during neural network training improved the final accuracy from 80% to 85%, highlighting the influence of batch-to-batch variations in both device fabrication and assay operation.¹⁸⁹ Moreover, when developing optimization models for μ PADs, flow-related behaviour must be incorporated into the governing equations, given the intrinsic dependence of paper-based microfluidics on capillary-driven transport.¹⁹⁴

Very recently, a ML-assisted optimization approach was also extended to distance-based μ PADs by Lv *et al.* in 2025.¹⁹⁵ They utilized ML for parameter optimization and engineering manufacturing of distance-based μ PADs, resulting in the reduction of experimental time and effort.

While ML- or DL-assisted μ PADs contribute to unlock the full analytical potential of these devices as hardware, software, and assay chemistry continue to co-evolve, several considerations must be kept in mind. These include the complex regulatory landscape, the possibility of erroneous or illogical outputs caused by unrepresented or underrepresented cases in training datasets (*e.g.*, rare diseases or specific patient subgroups), and the limited transparency of some ML systems.¹³² Implementing rigorous quality-control measures and recognizing that certain exceptional cases may remain unpredictable for ML or DL systems are therefore essential steps in responsible application of these techniques.

Conclusions

Since our previous review on μ PADs published in this journal in 2017, the field has continued to advance toward real-world applications. At that time, we pointed out three major challenges for μ PADs aimed at routine health checks: the necessity of complicated user operations, insufficient evaluation on long-term device storage stability, and reliance on detection equipment unfamiliar to general users. Thanks to the progress made in on-device sample pretreatment and smartphone integration, most studies targeting routine health checks have now achieved sample-in-answer-out functionality, and research focus has shifted towards the simplification of more complex assays, including immunoassays or nucleic acid testing. While assay operation has been simplified through automated sequential reagent delivery and device design innovation, there is still room for improvement in integration of off-device sample pretreatment steps such as for example blood separation and nucleic acid extraction. To comprehensively evaluate future reports on sample-in-answer-out μ PAD systems, we emphasize the importance of assessing in parallel the trade-off between the necessity for end-user reagent handling and long-term device storage stability, and the relationship between the number of operation steps and off-device

pretreatment requirements, together with time control needs. Meanwhile, long-term device storage stability, one of the challenges highlighted in our 2017 review, remains insufficiently addressed, even for μ PADs intended for routine health checks performed by end-users in non-clinical settings, in addition to evaluation criteria for acceptable signal deterioration not being standardized. Apart from the development of sample-in-answer-out systems, recent studies exploring automated sequential reagent addition, increased liquid flow rates, and semi-quantitative signal readout approaches represent foundational concepts for achieving fully integrated μ PAD versions for more complex assays in the future.

Technologies such as SERS- and bioluminescence-based signal detection, CRISPR-based assay methods, and ML or DL-assisted image analysis and data interpretation have only more recently gained significant momentum in the field of μ PADs. While SERS and bioluminescence still face major limitations in terms of the need of external Raman detecting modules and the instability of bioluminescent substrates, CRISPR-based assays and ML/DL approaches have already had significant impact in the field. Various CRISPR-based assays have been combined with μ PADs due to the flexibility of their signal transduction mechanisms and are now actively contributing to the development of fully integrated NAT platforms. ML- and DL-assisted image analysis and data interpretation have enhanced μ PAD performance without adding operational complexity, enabling shorter assay times without compromising sensitivity, minimizing sample matrix interference, and simplifying experimental optimization.

Finally, microchannel patterning methods on paper substrates are likely to become an increasingly critical issue for academic research. Currently, the wax printing method remains the most widely used technique for device prototyping in academic laboratories due to its simplicity, speed, and flexibility in design modification. However, with the discontinuation of commercially available wax printers, there is growing concern about the long-term sustainability of that approach. Although a range of alternative patterning methods has been reported,^{78,196–201} none have yet matched the ease of use and rapid turnaround time offered by wax printing.

Conflicts of interest

There are no conflicts to declare.

Data availability

No primary research results, software or code have been included, and no new data were generated or analysed as part of this review.

Supplementary information (SI): details of analytical performance of recent μ PAD examples (2018–2025) in medical diagnostic applications (immunoassays, nucleic acid tests, *etc.*). See DOI: <https://doi.org/10.1039/d5lc01085c>.



Acknowledgements

Y. T. gratefully acknowledges funding from JST SPRING, Grant Number JPMJSP2123. During the preparation of this work the authors used ChatGPT to improve the readability and language of the manuscript. While using this tool, the authors reviewed and edited the text as needed and take full responsibility for the content of the published article.

Notes and references

- J. P. Comer, *Anal. Chem.*, 1956, **28**, 1748–1750.
- A. H. Free, E. C. Adams, M. L. Kercher, H. M. Free and M. H. Cook, *Clin. Chem.*, 1957, **3**, 163–168.
- R. L. Campbell, D. B. Wagner and J. P. O'connell, *US Pat.*, 4703017, 1987.
- R. W. Rosenstein and T. G. Bloomster, *US Pat.*, 4855240, 1989.
- A. W. Martinez, S. T. Phillips, M. J. Butte and G. M. Whitesides, *Angew. Chem., Int. Ed.*, 2007, **46**, 1318–1320.
- D. M. Cate, J. A. Adkins, J. Mettakoonpitak and C. S. Henry, *Anal. Chem.*, 2015, **87**, 19–41.
- E. Noviana, T. Ozer, C. S. Carrell, J. S. Link, C. McMahon, I. Jang and C. S. Henry, *Chem. Rev.*, 2021, **121**, 11835–11885.
- M.-N. Tsaloglou, D. C. Christodouleas, J. Milette, K. Milkey, I. C. Romine, J. Im, S. Lathwal, D. T. Selvam, H. D. Sikes and G. M. Whitesides, *Lab Chip*, 2025, **25**, 741–751.
- E. Carrilho, A. W. Martinez and G. M. Whitesides, *Anal. Chem.*, 2009, **81**, 7091–7095.
- K. Yamada, H. Shibata, K. Suzuki and D. Citterio, *Lab Chip*, 2017, **17**, 1206–1249.
- A. Sena-Torralba, R. Álvarez-Diduk, C. Parolo, A. Piper and A. Merkoçi, *Chem. Rev.*, 2022, **122**, 14881–14910.
- J. Budd, B. S. Miller, N. E. Weckman, D. Cherkaoui, D. Huang, A. T. Decruz, N. Fongwen, G.-R. Han, M. Broto, C. S. Estcourt, J. Gibbs, D. Pillay, P. Sonnenberg, R. Meurant, M. R. Thomas, N. Keegan, M. M. Stevens, E. Nastouli, E. J. Topol, A. M. Johnson, M. Shahmanesh, A. Ozcan, J. J. Collins, M. Fernandez Suarez, B. Rodriguez, R. W. Peeling and R. A. McKendry, *Nat. Rev. Bioeng.*, 2023, **1**, 13–31.
- J. L. Chen, D. I. Njoku, C. Tang, Y. Gao, J. Chen, Y.-K. Peng, H. Sun, G. Mao, M. Pan and N. F.-Y. Tam, *Small Methods*, 2024, **8**, 2400155.
- P. Aryal and C. S. Henry, *Front. Lab Chip Technol.*, 2024, **3**, 1467423.
- P. M. Kalligosfyri and S. Cinti, *ACS Mater. Lett.*, 2024, **6**, 1184–1198.
- J. D. Bishop, H. V. Hsieh, D. J. Gasperino and B. H. Weigl, *Lab Chip*, 2019, **19**, 2486–2499.
- V.-T. Nguyen, S. Song, S. Park and C. Joo, *Biosens. Bioelectron.*, 2020, **152**, 112015.
- J. R. Choi, K. W. Yong, R. Tang, Y. Gong, T. Wen, F. Li, B. Pingguan-Murphy, D. Bai and F. Xu, *TrAC, Trends Anal. Chem.*, 2017, **93**, 37–50.
- Z. Li, Y. Bai, M. You, J. Hu, C. Yao, L. Cao and F. Xu, *Biosens. Bioelectron.*, 2021, **177**, 112952.
- A. C. Mora and C. R. Mace, *ACS Sens.*, 2025, **10**, 3795–3805.
- H. Fu, P. Song, Q. Wu, C. Zhao, P. Pan, X. Li, N. Y. K. Li-Jessen and X. Liu, *Microsyst. Nanoeng.*, 2019, **5**, 50.
- Y.-S. Chien, U.-I. Wu, Y.-H. Pan and C.-F. Chen, *Biosens. Bioelectron.*, 2025, **287**, 117724.
- K. Tenda, B. Van Gerven, R. Arts, Y. Hiruta, M. Merckx and D. Citterio, *Angew. Chem., Int. Ed.*, 2018, **57**, 15369–15373.
- D. Lee, C.-H. Chu and A. F. Sarioglu, *ACS Sens.*, 2021, **6**, 3204–3213.
- P. Q. Nguyen, L. R. Soenksen, N. M. Donghia, N. M. Angenent-Mari, H. De Puig, A. Huang, R. Lee, S. Slomovic, T. Galbersanini, G. Lansberry, H. M. Sallum, E. M. Zhao, J. B. Niemi and J. J. Collins, *Nat. Biotechnol.*, 2021, **39**, 1366–1374.
- T. Boonpoempoon, W. Wonsawat and T. Kaneta, *Sci. Rep.*, 2019, **9**, 12951.
- K. Inaba, T. Moriwaki, T. Maruyama and K. Morita, *ACS Appl. Nano Mater.*, 2025, **8**, 15572–15580.
- T. Zhang, R. Deng, Y. Wang, C. Wu, K. Zhang, C. Wang, N. Gong, R. Ledesma-Amaro, X. Teng, C. Yang, T. Xue, Y. Zhang, Y. Hu, Q. He, W. Li and J. Li, *Nat. Biomed. Eng.*, 2022, **6**, 957–967.
- S. K. Biswas, S. Chatterjee, S. Bandyopadhyay, S. Kar, N. K. Som, S. Saha and S. Chakraborty, *ACS Sens.*, 2021, **6**, 1077–1085.
- C.-A. Chen, H. Yuan, C.-W. Chen, Y.-S. Chien, W.-H. Sheng and C.-F. Chen, *Lab Chip*, 2021, **21**, 1908–1915.
- A. Yakoh, E. Mehmeti, K. Kalcher and S. Chaiyo, *Anal. Chem.*, 2022, **94**, 5893–5900.
- S. Mansouri, S. Boulares, S. Chabchoub, Y. Alharbi and A. Alqahtani, *Microchem. J.*, 2025, **209**, 112670.
- K. Yamada, K. Suzuki and D. Citterio, *ACS Sens.*, 2017, **2**, 1247–1254.
- J. E. Butler, *J. Immunoassay Immunochem.*, 2000, **21**, 165–209.
- E. Fu, T. Liang, P. Spicar-Mihalic, J. Houghtaling, S. Ramachandran and P. Yager, *Anal. Chem.*, 2012, **84**, 4574–4579.
- A. Apilux, Y. Ukita, M. Chikae, O. Chailapakul and Y. Takamura, *Lab Chip*, 2013, **13**, 126–135.
- B. Lutz, T. Liang, E. Fu, S. Ramachandran, P. Kauffman and P. Yager, *Lab Chip*, 2013, **13**, 2840–2847.
- C. Srisomwat, A. Yakoh, N. Chuaypen, P. Tangkijvanich, T. Vilaivan and O. Chailapakul, *Anal. Chem.*, 2021, **93**, 2879–2887.
- K. Yin, X. Ding, Z. Li, M. M. Sfeir, E. Ballesteros and C. Liu, *Lab Chip*, 2021, **21**, 2730–2737.
- J. Han, A. Qi, J. Zhou, G. Wang, B. Li and L. Chen, *ACS Sens.*, 2018, **3**, 1789–1794.
- A. Yakoh, S. Chaiyo, W. Siangproh and O. Chailapakul, *ACS Sens.*, 2019, **4**, 1211–1221.
- Y. Chen, Y. Hu and X. Lu, *ACS Sens.*, 2023, **8**, 2331–2339.
- K. Maejima, Y. Hiruta and D. Citterio, *Anal. Chem.*, 2020, **92**, 4749–4754.
- K. Khachornsakkul, W. Dungchai and N. Pamme, *ACS Sens.*, 2022, **7**, 2410–2419.



- 45 D. W. Bradbury, M. Azimi, A. J. Diaz, A. A. Pan, C. H. Falktoft, B. M. Wu and D. T. Kamei, *Anal. Chem.*, 2019, **91**, 12046–12054.
- 46 T. Akyazi, A. Tudor, D. Diamond, L. Basabe-Desmonts, L. Florea and F. Benito-Lopez, *Sens. Actuators, B*, 2018, **261**, 372–378.
- 47 G.-R. Han, H. Ki and M.-G. Kim, *ACS Appl. Mater. Interfaces*, 2020, **12**, 1885–1894.
- 48 R. Tang, H. Yang, J. R. Choi, Y. Gong, J. Hu, T. Wen, X. Li, B. Xu, Q. Mei and F. Xu, *Microchim. Acta*, 2017, **184**, 2141–2150.
- 49 J. Park and J.-K. Park, *Sens. Actuators, B*, 2017, **246**, 1049–1055.
- 50 E. B. Strong, C. Knutsen, J. T. Wells, A. R. Jangid, M. L. Mitchell, N. W. Martinez and A. W. Martinez, *Inventions*, 2019, **4**, 20.
- 51 D. Lee, T. Ozkaya-Ahmadov, C.-H. Chu, M. Boya, R. Liu and A. F. Sarioglu, *Sci. Adv.*, 2021, **7**, eabf9833.
- 52 C. Dai, H. Huang, Y. Zhang, Y. Liu, Y. Tao, T. Chen, Y. Zhang, C. Wan, S. Li, Z. Miao, Y. Li, P. Chen and B.-F. Liu, *Biosens. Bioelectron.*, 2026, **292**, 118083.
- 53 R. B. Channon, M. P. Nguyen, A. G. Scorzelli, E. M. Henry, J. Volckens, D. S. Dandy and C. S. Henry, *Lab Chip*, 2018, **18**, 793–802.
- 54 N. Raj, V. Breedveld and D. W. Hess, *Sens. Actuators, B*, 2020, **320**, 128606.
- 55 H. Fu, Z. Qin, X. Li, Y. Pan, H. Xu, P. Pan, P. Song and X. Liu, *ACS Sens.*, 2023, **8**, 3574–3584.
- 56 S. Yang, J. Zhu, L. Yang, H. Fa, Y. Wang, D. Huo, C. Hou, D. Zhong and M. Yang, *ACS Sens.*, 2025, **10**, 133–147.
- 57 H. Suzuki, G. Tong, P. Nath, Y. Hiruta and D. Citterio, *ACS Sens.*, 2025, **10**, 1811–1821.
- 58 P. Biswas, G. N. Mukunthan Sulochana, T. N. Banuprasad, P. Goyal, D. Modak, A. K. Ghosh and S. Chakraborty, *ACS Sens.*, 2022, **7**, 3720–3729.
- 59 S. Liu, T. Yu, L. Song, K. Kalantar-Zadeh and G. Liu, *ACS Sens.*, 2025, **10**, 4569–4579.
- 60 M. Wang, J. Qi, F. Li, Y. Liu, J. Xiang, B. Li, X. Zhuang, L. Chen and X. Fu, *Sens. Actuators, B*, 2026, **446**, 138643.
- 61 E. W. Washburn, *Phys. Rev.*, 1921, **17**, 273–283.
- 62 D. M. Cate, W. Dungchai, J. C. Cunningham, J. Volckens and C. S. Henry, *Lab Chip*, 2013, **13**, 2397–2404.
- 63 J. E. Schonhorn, S. C. Fernandes, A. Rajaratnam, R. N. Deraney, J. P. Rolland and C. R. Mace, *Lab Chip*, 2014, **14**, 4653–4658.
- 64 S. Jahanshahi-Anbuhi, P. Chavan, C. Sicard, V. Leung, S. M. Z. Hossain, R. Pelton, J. D. Brennan and C. D. M. Filipe, *Lab Chip*, 2012, **12**, 5079–5085.
- 65 C. K. Camplisson, K. M. Schilling, W. L. Pedrotti, H. A. Stone and A. W. Martinez, *Lab Chip*, 2015, **15**, 4461–4466.
- 66 J. A. Adkins, E. Noviana and C. S. Henry, *Anal. Chem.*, 2016, **88**, 10639–10647.
- 67 R. B. Channon, Y. Yang, K. M. Feibelman, B. J. Geiss, D. S. Dandy and C. S. Henry, *Anal. Chem.*, 2018, **90**, 7777–7783.
- 68 V. Soum, S. Park, A. I. Brilian, J.-Y. Choi, Y. Lee, W. Kim, O.-S. Kwon and K. Shin, *Lab Chip*, 2020, **20**, 1601–1611.
- 69 S. Boonkaew, A. Yakoh, N. Chuaypen, P. Tangkijvanich, S. Rengpipat, W. Siangproh and O. Chailapakul, *Biosens. Bioelectron.*, 2021, **193**, 113543.
- 70 K. Phoonsawat, T. Ozer, W. Dungchai and C. S. Henry, *Analyst*, 2022, **147**, 4517–4524.
- 71 P. Aryal, A. W. Indrianingsih and C. S. Henry, *Green Anal. Chem.*, 2024, **8**, 100091.
- 72 C. Srisomwat, N. Bawornnithichaiyakul, S. Khonyoung, W. Tiyapongpattana, S. Butcha, N. Youngvises and O. Chailapakul, *Talanta*, 2024, **280**, 126770.
- 73 X. Chen, H. Li, X. Li, M. Zhang, Q. He, J. Zhou, J. Zhong, H. Chen, Y. Shi, H. Chen, H. Zhang, L. T. Chu and W. Guo, *Lab Chip*, 2025, **25**, 3839–3848.
- 74 Y. B. Cho, D. C. Nguyen, S. H. Hua and Y. S. Kim, *Microchem. J.*, 2024, **201**, 110532.
- 75 P. Aryal, E. Brack, T. Alexander and C. S. Henry, *Anal. Chem.*, 2023, **95**, 5820–5827.
- 76 R. K. Arun, N. Priyadarshini, K. Chaudhury, N. Chanda, G. Biswas and S. Chakraborty, *J. Micromech. Microeng.*, 2016, **26**, 105008.
- 77 H. Shigemori, K. Maejima, H. Shibata, Y. Hiruta and D. Citterio, *Microchim. Acta*, 2023, **190**, 48.
- 78 C. Park, Y. D. Han, H. V. Kim, J. Lee, H. C. Yoon and S. Park, *Lab Chip*, 2018, **18**, 1533–1538.
- 79 A. Lomae, K. Teekayupak, P. Preechakasedkit, E. Pasomsub, T. Ozer, C. S. Henry, D. Citterio, T. Vilaivan, O. Chailapakul and N. Ruecha, *Talanta*, 2024, **279**, 126613.
- 80 J. S. Link, J. O'Donnell-Sloan, S. Curdts, B. J. Geiss, D. S. Dandy and C. S. Henry, *Anal. Chem.*, 2024, **96**, 4111–4119.
- 81 C. Prakobdi, T. A. Baldo, P. Aryal, J. Link, P. Saetear and C. S. Henry, *Anal. Methods*, 2024, **16**, 2489–2495.
- 82 I. Macleod Briongos, Z. D. Call, C. S. Henry and D. L. Bark, *Microfluid. Nanofluid.*, 2023, **27**, 70.
- 83 J. Yang, X. Feng, H. Li, P. Chang, X. Ren and X. Li, *ACS Sens.*, 2025, **10**, 5623–5632.
- 84 F. T. S. M. Ferreira, R. B. R. Mesquita and A. O. S. S. Rangel, *Microchem. J.*, 2023, **193**, 109102.
- 85 K. Khachornsakkul and W. Dungchai, *ACS Sens.*, 2021, **6**, 1339–1347.
- 86 Y. Li, L. Zhou, W. Ni, Q. Luo, C. Zhu and Y. Wu, *Anal. Chem.*, 2019, **91**, 14838–14841.
- 87 M. Celina, K. T. Gillen and R. A. Assink, *Polym. Degrad. Stab.*, 2005, **90**, 395–404.
- 88 S. Minnikanti, G. Diao, J. J. Pancrazio, X. Xie, L. Rieth, F. Solzbacher and N. Peixoto, *Acta Biomater.*, 2014, **10**, 960–967.
- 89 P. Panjan, V. Virtanen and A. M. Sesay, *Talanta*, 2017, **170**, 331–336.
- 90 L. Hongtanee, S. Chaiyo, H. Wu and A. Yakoh, *Adv. Healthcare Mater.*, 2025, **14**, 2404320.
- 91 N. Thueankhum, L. Hongtanee, U. Boonyuen, A. Yakoh and K. Charoenkitamorn, *Anal. Chem.*, 2025, **97**, 20771–20779.
- 92 K. Fan, J. Zeng, C. Yang, G. Wang, K. Lian, X. Zhou, Y. Deng and G. Liu, *ACS Sens.*, 2022, **7**, 2049–2057.
- 93 A. Yamaguchi, S. Oyama, A. Ishida, T. Enomoto, N. Sanari, H. Miyaguchi and M. Tokeshi, *ACS Appl. Bio Mater.*, 2025, **8**, 1699–1706.



- 94 Y. Tanifuji, H. Suzuki, G. Tong, Y. Hiruta and D. Citterio, *Anal. Methods*, 2024, **16**, 4143–4149.
- 95 M. M. Calabretta, R. Álvarez-Diduk, E. Michelini, A. Roda and A. Merkoçi, *Biosens. Bioelectron.*, 2020, **150**, 111902.
- 96 I. Lewińska, M. Ścibisz and Ł. Tymecki, *Anal. Chim. Acta*, 2024, **1308**, 342639.
- 97 K. A. Ganaja, C. A. Chaplan, J. Zhang, N. W. Martinez and A. W. Martinez, *Anal. Chem.*, 2017, **89**, 5333–5341.
- 98 S. S. Nadar, P. D. Patil, M. S. Tiwari and D. J. Ahirrao, *Crit. Rev. Biotechnol.*, 2021, **41**, 1046–1080.
- 99 A. Baranwal, R. Shukla and V. Bansal, *TrAC, Trends Anal. Chem.*, 2024, **172**, 117573.
- 100 B. Das, J. L. Franco, N. Logan, P. Balasubramanian, M. I. Kim and C. Cao, *Nano-Micro Lett.*, 2021, **13**, 193.
- 101 K. Khachornsakkul, F. J. Rybicki and S. Sonkusale, *Talanta*, 2023, **260**, 124538.
- 102 N. Kitchawengkul, A. Prakobkij, R. Saenmuangchinn, D. Citterio, D. Nacapricha and P. Jarujamrus, *Sens. Actuators, B*, 2025, **435**, 137671.
- 103 D. Cheng, J. Qin, Y. Feng and J. Wei, *Biosensors*, 2021, **11**, 258.
- 104 L. Wang, Y. Chen, Y. Ji, L. Wang, X. Liu, F. Wang and C. Li, *Anal. Chem.*, 2024, **96**, 11353–11365.
- 105 S. E. Son, S. H. Cheon, W. Hur, H. B. Lee, D. H. Kim, C. H. Ha, S. J. Lee, D. K. Han and G. H. Seong, *Biosens. Bioelectron.*, 2024, **243**, 115752.
- 106 S. Yang, L. Zhao, X. Yang, L. Yang, H. Fa, Y. Wang, D. Huo, C. Hou, D. Zhong and M. Yang, *Talanta*, 2024, **278**, 126523.
- 107 Y. Qin, Y. Qin, J. Sun, J. Qian, J. Yuan, J. Yao and M. Zhang, *Chem. Eng. J.*, 2025, **514**, 163033.
- 108 Q. H. Nguyen, D. H. Lee, P. T. Nguyen, P. G. Le and M. I. Kim, *Chem. Eng. J.*, 2023, **454**, 140541.
- 109 G. G. Lewis, M. J. DiTucci and S. T. Phillips, *Angew. Chem., Int. Ed.*, 2012, **51**, 12707–12710.
- 110 Y. Zhang, J. Fan, J. Nie, S. Le, W. Zhu, D. Gao, J. Yang, S. Zhang and J. Li, *Biosens. Bioelectron.*, 2015, **73**, 13–18.
- 111 M. Li, J. Tian, M. Al-Tamimi and W. Shen, *Angew. Chem., Int. Ed.*, 2012, **51**, 5497–5501.
- 112 S. Lee, J. Park and J.-K. Park, *Sens. Actuators, B*, 2018, **273**, 322–327.
- 113 A. Teprek, V. Poetri Artono, W. Waiyawat, A. Limsakul, J. Shiowatana and A. Siripinyanond, *Microchem. J.*, 2020, **158**, 105284.
- 114 K. Khachornsakkul, D. Phuengkasem, K. Palkuntod, W. Sangkharoek, O. Jamjumrus and W. Dungchai, *ACS Sens.*, 2022, **7**, 2093–2101.
- 115 A. Katoh, K. Maejima, Y. Hiruta and D. Citterio, *Analyst*, 2020, **145**, 6071–6078.
- 116 M. Yang, W. Zhang, W. Zheng, F. Cao and X. Jiang, *Lab Chip*, 2017, **17**, 3874–3882.
- 117 Y. Manmana, S. Kinugasa, Y. Hiruta and D. Citterio, *Anal. Chem.*, 2025, **97**, 1500–1506.
- 118 A. Burklund, H. K. Saturley-Hall, F. A. Franchina, J. E. Hill and J. X. J. Zhang, *Biosens. Bioelectron.*, 2019, **128**, 97–103.
- 119 K. Yamada, D. Citterio and C. S. Henry, *Lab Chip*, 2018, **18**, 1485–1493.
- 120 S. Ohta, R. Hiraoka, Y. Hiruta and D. Citterio, *Lab Chip*, 2022, **22**, 717–726.
- 121 S. M. Russell, A. Alba-Patiño, M. Borges and R. de la Rica, *ACS Sens.*, 2018, **3**, 1712–1718.
- 122 Y.-Q. Yang, Y.-C. Yang, M.-H. Liu and Y.-H. Chan, *Anal. Chem.*, 2020, **92**, 1493–1501.
- 123 V. Oncescu, D. O'Dell and D. Erickson, *Lab Chip*, 2013, **13**, 3232–3238.
- 124 A. K. Yetisen, J. L. Martinez-Hurtado, A. Garcia-Melendrez, F. da Cruz Vasconcellos and C. R. Lowe, *Sens. Actuators, B*, 2014, **196**, 156–160.
- 125 G. Chen, C. Fang, H. H. Chai, Y. Zhou, W. Yun Li and L. Yu, *Sens. Actuators, B*, 2019, **281**, 253–261.
- 126 S. Nie and S. R. Emory, *Science*, 1997, **275**, 1102–1106.
- 127 K. Kneipp, Y. Wang, H. Kneipp, L. T. Perelman, I. Itzkan, R. R. Dasari and M. S. Feld, *Phys. Rev. Lett.*, 1997, **78**, 1667–1670.
- 128 A. Roda, M. Mirasoli, E. Michelini, M. Di Fusco, M. Zangheri, L. Cevenini, B. Roda and P. Simoni, *Biosens. Bioelectron.*, 2016, **76**, 164–179.
- 129 J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee, P. Essletzbichler, A. J. Dy, J. Joung, V. Verdine, N. Donghia, N. M. Daringer and C. A. Freije, *Science*, 2017, **356**, 438–442.
- 130 J. S. Chen, E. Ma, L. B. Harrington, M. Da Costa, X. Tian, J. M. Palefsky and J. A. Doudna, *Science*, 2018, **360**, 436–439.
- 131 M. Bhaiyya, D. Panigrahi, P. Rewatkar and H. Haick, *ACS Sens.*, 2024, **9**, 4495–4519.
- 132 G.-R. Han, A. Goncharov, M. Eryilmaz, S. Ye, B. Palanisamy, R. Ghosh, F. Lisi, E. Rogers, D. Guzman, D. Yigci, S. Tasoglu, D. Di Carlo, K. Goda, R. A. McKendry and A. Ozcan, *Nat. Commun.*, 2025, **16**, 3165.
- 133 J. Langer, D. Jimenez de Aberasturi, J. Aizpurua, R. A. Alvarez-Puebla, B. Auguie, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G. Brolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J. Garcia de Abajo, R. Goodacre, D. Graham, A. J. Haes, C. L. Haynes, C. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le Ru, H. K. Lee, J.-F. Li, X. Y. Ling, S. A. Maier, T. Mayerhöfer, M. Moskovits, K. Murakoshi, J.-M. Nam, S. Nie, Y. Ozaki, I. Pastoriza-Santos, J. Perez-Juste, J. Popp, A. Pucci, S. Reich, B. Ren, G. C. Schatz, T. Shegai, S. Schlücker, L.-L. Tay, K. G. Thomas, Z.-Q. Tian, R. P. Van Duyne, T. Vo-Dinh, Y. Wang, K. A. Willets, C. Xu, H. Xu, Y. Xu, Y. S. Yamamoto, B. Zhao and L. M. Liz-Marzán, *ACS Nano*, 2020, **14**, 28–117.
- 134 T. Itoh, M. Procházka, Z.-C. Dong, W. Ji, Y. S. Yamamoto, Y. Zhang and Y. Ozaki, *Chem. Rev.*, 2023, **123**, 1552–1634.
- 135 C. H. Lee, L. Tian and S. Singamaneni, *ACS Appl. Mater. Interfaces*, 2010, **2**, 3429–3435.
- 136 W. W. Yu and I. M. White, *Analyst*, 2013, **138**, 1020–1025.
- 137 Y. Cao, Y. Sun, R.-J. Yu and Y.-T. Long, *Microchim. Acta*, 2023, **191**, 8.
- 138 V. Eskandari, H. Sahbafar, L. Zeinalizad, R. Marashipour and A. Hadi, *J. Comput. Appl. Mech.*, 2022, **53**, 142–156.
- 139 W. Y. Lim, C.-H. Goh, T. M. Thevarajah, B. T. Goh and S. M. Khor, *Biosens. Bioelectron.*, 2020, **147**, 111792.



- 140 S. Mabbott, S. C. Fernandes, M. Schechinger, G. L. Cote, K. Faulds, C. R. Mace and D. Graham, *Analyst*, 2020, **145**, 983–991.
- 141 S. Lee, H. Dang, J.-I. Moon, K. Kim, Y. Joung, S. Park, Q. Yu, J. Chen, M. Lu, L. Chen, S.-W. Joo and J. Choo, *Chem. Soc. Rev.*, 2024, **53**, 5394–5427.
- 142 F. Zeng, W. Duan, B. Zhu, T. Mu, L. Zhu, J. Guo and X. Ma, *Anal. Chem.*, 2019, **91**, 1064–1070.
- 143 F. Zeng, T. Mou, C. Zhang, X. Huang, B. Wang, X. Ma and J. Guo, *Analyst*, 2019, **144**, 137–142.
- 144 R. Griss, A. Schena, L. Reymond, L. Patiny, D. Werner, C. E. Tinberg, D. Baker and K. Johnsson, *Nat. Chem. Biol.*, 2014, **10**, 598–603.
- 145 L. Xue, Q. Yu, R. Griss, A. Schena and K. Johnsson, *Angew. Chem., Int. Ed.*, 2017, **56**, 7112–7116.
- 146 K. Tomimuro, K. Tenda, Y. Ni, Y. Hiruta, M. Merckx and D. Citterio, *ACS Sens.*, 2020, **5**, 1786–1794.
- 147 Y. Yang, A. Inoue, T. Yasuda, H. Ueda, B. Zhu and T. Kitaguchi, *ACS Sens.*, 2024, **9**, 5955–5965.
- 148 A. A. Shalaby, A. Salah, A. Ishida, M. Maeki and M. Tokeshi, *Biosens. Bioelectron.: X*, 2025, **24**, 100621.
- 149 H. Martínez-Pérez-Cejuela, M. M. Calabretta, V. Bocci, M. D'Elia and E. Michelini, *Biosensors*, 2023, **13**, 451.
- 150 J. P. Hunt, E. L. Zhao, T. J. Free, M. Soltani, C. A. Warr, A. B. Benedict, M. K. Takahashi, J. S. Griffiths, W. G. Pitt and B. C. Bundy, *New Biotechnol.*, 2022, **66**, 53–60.
- 151 A. Lopreside, L. Montali, B. Wang, A. Tassoni, M. Ferri, M. M. Calabretta and E. Michelini, *Biosens. Bioelectron.*, 2021, **194**, 113569.
- 152 F. Nazir, D. Gregucci, M. M. Calabretta, C. Cambrea, P. Vahidi, S. Lavrnić, A. Toscano and E. Michelini, *Anal. Chem.*, 2025, **97**, 18092–18100.
- 153 R. Kurita and R. Nishihara, *Sens. Actuators, B*, 2025, **423**, 136700.
- 154 R. Shimazu, K. Tomimuro, Y. Ni, C. Malegori, V. Hamedpour, Y. Hiruta, P. Oliveri, M. Merckx and D. Citterio, *Sens. Actuators, B*, 2022, **352**, 131002.
- 155 Y. Mizui, M. Eguchi, M. Tanaka, Y. Ikeda, H. Yoshimura, T. Ozawa, D. Citterio and Y. Hiruta, *Org. Biomol. Chem.*, 2021, **19**, 579–586.
- 156 M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna and E. Charpentier, *Science*, 2012, **337**, 816–821.
- 157 Y. Dai, Y. Wu, G. Liu and J. J. Gooding, *Angew. Chem., Int. Ed.*, 2020, **59**, 20754–20766.
- 158 M. M. Kaminski, O. O. Abudayyeh, J. S. Gootenberg, F. Zhang and J. J. Collins, *Nat. Biomed. Eng.*, 2021, **5**, 643–656.
- 159 K. Pardee, A. A. Green, M. K. Takahashi, D. Braff, G. Lambert, J. W. Lee, T. Ferrante, D. Ma, N. Donghia and M. Fan, *Cell*, 2016, **165**, 1255–1266.
- 160 J. S. Gootenberg, O. O. Abudayyeh, M. J. Kellner, J. Joung, J. J. Collins and F. Zhang, *Science*, 2018, **360**, 439–444.
- 161 M. J. Kellner, J. G. Koob, J. S. Gootenberg, O. O. Abudayyeh and F. Zhang, *Nat. Protoc.*, 2019, **14**, 2986–3012.
- 162 J. P. Broughton, X. Deng, G. Yu, C. L. Fasching, V. Servellita, J. Singh, X. Miao, J. A. Streithorst, A. Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E. Hsu, W. Gu, S. Miller, C.-Y. Pan, H. Guevara, D. A. Wadford, J. S. Chen and C. Y. Chiu, *Nat. Biotechnol.*, 2020, **38**, 870–874.
- 163 V. Lapee-e, S. Nuanualsuwan, L. Hongtanee and A. Yakoh, *Microchem. J.*, 2025, **211**, 113055.
- 164 S. Dalgan and Q. Wei, *Adv. Sens. Res.*, 2025, e00036.
- 165 D. Huang, D. Ni, M. Fang, Z. Shi and Z. Xu, *Anal. Chem.*, 2021, **93**, 16965–16973.
- 166 P. Li, S. Xu, Z. Dong, H. Liu, J. Huang, X. Deng, Y. Tao, H. Liu, Z. Lin and Z. Li, *Biosens. Bioelectron.*, 2024, **271**, 117087.
- 167 R. Yang, X. Guan, J. Zhang, J. Moon, C. Guo, Z. Jia, C. Hou, U. Ganbaatar, S. Tricarico, A. W. K. Ma and C. Liu, *Biosens. Bioelectron.*, 2024, **271**, 117054.
- 168 X. Zhao, Y. He, S. Shao, Q. Ci, L. Chen, X. Lu, Q. Liu and J. Chen, *ACS Sens.*, 2024, **9**, 2413–2420.
- 169 X. Guan, R. Yang, J. Zhang, J. Moon, C. Hou, C. Guo, L. Avery, D. Scarola, D. S. Roberts, R. LaSala and C. Liu, *Adv. Sci.*, 2025, **12**, 2411021.
- 170 E. Hanson, N. Kalla, R. J. Tharu, M. M. Demir, B. H. Tok, M. A. Canbaz and M. V. Yigit, *Small*, 2025, **21**, 2500784.
- 171 M. A. English, L. R. Soenksen, R. V. Gayet, H. de Puig, N. M. Angenent-Mari, A. S. Mao, P. Q. Nguyen and J. J. Collins, *Science*, 2019, **365**, 780–785.
- 172 L. Li, G. Wang, Y. Rong, Y. Zhang, J. Huang, Y. Zhang, S. Ge, K. Cui, L. Zhang and J. Yu, *Nano Energy*, 2023, **116**, 108768.
- 173 Y. Zhang, L. Gao, Z. Shi, Q. Wu and X. Miao, *Bioelectrochemistry*, 2025, **164**, 108916.
- 174 Y. Zhang, K. Lv, Y. Zhang, Q. Mi, D. Ye, X. Chen and J. Zhang, *Chem. Eng. J.*, 2025, **520**, 165900.
- 175 A. Sen, M. Masetty, S. Weerakoon, C. Morris, J. S. Yadav, S. Apewokin, J. Trannguyen, M. Broom and A. Priye, *Biosens. Bioelectron.*, 2024, **257**, 116292.
- 176 Y. Joung, D. K. Han, H. Jang, T. Kang, L. Chen and J. Choo, *ACS Sens.*, 2025, **10**, 6253–6262.
- 177 Y. Tanifuji, G. Tong, Y. Hiruta and D. Citterio, *Analyst*, 2024, **149**, 4932–4939.
- 178 H.-A. Joung, Z. S. Ballard, J. Wu, D. K. Tseng, H. Teshome, L. Zhang, E. J. Horn, P. M. Arnaboldi, R. J. Dattwyler, O. B. Garner, D. Di Carlo and A. Ozcan, *ACS Nano*, 2020, **14**, 229–240.
- 179 Z. S. Ballard, H.-A. Joung, A. Goncharov, J. Liang, K. Nugroho, D. Di Carlo, O. B. Garner and A. Ozcan, *npj Digit. Med.*, 2020, **3**, 66.
- 180 Q. Bao, G. Li, W. Cheng, Z. Yang, Z. Qu, J. Wei and L. Lin, *RSC Adv.*, 2023, **13**, 23788–23795.
- 181 L. Bi, H. Zhang, C. Mu, K. Sun, H. Chen, Z. Zhang and L. Chen, *J. Hazard. Mater.*, 2025, **494**, 138694.
- 182 A. Goncharov, H.-A. Joung, R. Ghosh, G.-R. Han, Z. S. Ballard, Q. Maloney, A. Bell, C. T. Z. Aung, O. B. Garner, D. D. Carlo and A. Ozcan, *Small*, 2023, **19**, 2300617.
- 183 M. Eryilmaz, A. Goncharov, G.-R. Han, H.-A. Joung, Z. S. Ballard, R. Ghosh, Y. Zhang, D. Di Carlo and A. Ozcan, *ACS Nano*, 2024, **18**, 16819–16831.
- 184 R. Ghosh, H.-A. Joung, A. Goncharov, B. Palanisamy, K. Ngo, K. Pejcinovic, N. Krockenberger, E. J. Horn, O. B. Garner, E. Ghazal, A. O'Kula, P. M. Arnaboldi, R. J.



- Dattwyler, A. Ozcan and D. Di Carlo, *Nat. Commun.*, 2024, **15**, 7124.
- 185 G.-R. Han, A. Goncharov, M. Eryilmaz, H.-A. Joung, R. Ghosh, G. Yim, N. Chang, M. Kim, K. Ngo, M. Veszpremi, K. Liao, O. B. Garner, D. Di Carlo and A. Ozcan, *ACS Nano*, 2024, **18**, 27933–27948.
- 186 H. Sun, L. Xiong, Y. Huang, X. Chen, Y. Yu, S. Ye, H. Dong, Y. Jia and W. Zhang, *Fundam. Res.*, 2022, **2**, 476–486.
- 187 J. Zhu, K. Hoettges, Y. Wang, H. Ma, P. Song, Y. Hu, E. G. Lim and Q. Zhang, *Anal. Chem.*, 2025, **97**, 4515–4523.
- 188 Ö. B. Mercan, V. Kılıç and M. Şen, *Sens. Actuators, B*, 2021, **329**, 129037.
- 189 Q. Ning, W. Zheng, H. Xu, A. Zhu, T. Li, Y. Cheng, S. Feng, L. Wang, D. Cui and K. Wang, *Anal. Bioanal. Chem.*, 2022, **414**, 3959–3970.
- 190 S. Duan, T. Cai, J. Zhu, X. Yang, E. G. Lim, K. Huang, K. Hoettges, Q. Zhang, H. Fu, Q. Guo, X. Liu, Z. Yang and P. Song, *Anal. Chim. Acta*, 2023, **1248**, 340868.
- 191 J. S. Y. Low, T. M. Thevarajah, S. W. Chang and S. M. Khor, *Sens. Actuators, B*, 2023, **394**, 134403.
- 192 H.-J. Jang, H.-A. Joung, A. Goncharov, A. G. Kanegusuku, C. W. Chan, K.-T. J. Yeo, W. Zhuang, A. Ozcan and J. Chen, *ACS Nano*, 2024, **18**, 24792–24802.
- 193 G.-R. Han, A. Goncharov, M. Eryilmaz, S. Ye, H.-A. Joung, R. Ghosh, E. Ngo, A. Tomoeda, Y. Lee, K. Ngo, E. Melton, O. B. Garner, D. Di Carlo and A. Ozcan, *Small*, 2025, **21**, 2411585.
- 194 D. M. Y. Tay, S. Kim, Y. Hao, E. H. Yee, H. Jia, S. M. Vleck, M. Chilekwa, J. Voldman and H. D. Sikes, *Biosens. Bioelectron.*, 2023, **222**, 114977.
- 195 K. Lv, Y. Zhang, K. Tang, W. Huang, F. Chen, M. Chen, Y. Wang and J. Zhang, *ACS Sens.*, 2025, **10**, 7002–7013.
- 196 A. Chauhan and B. J. Toley, *Anal. Chem.*, 2021, **93**, 8954–8961.
- 197 N. Raj, V. Breedveld and D. W. Hess, *Microfluid. Nanofluid.*, 2021, **25**, 47.
- 198 R. A. Ruiz, J. L. Gonzalez, M. Vazquez-Alvarado, N. W. Martinez and A. W. Martinez, *Anal. Chem.*, 2022, **94**, 8833–8837.
- 199 S. Seetasang and T. Kaneta, *ACS Sens.*, 2022, **7**, 1194–1200.
- 200 T. Monju, M. Hirakawa, S. Kuboyama, R. Saiki and A. Ishida, *Sens. Actuators, B*, 2023, **375**, 132886.
- 201 L. Meng, D. Cao, J. O. Pedersen, G. Greczynski, V. Rogoz, W. Limbut and M. Eriksson, *ACS Appl. Mater. Interfaces*, 2025, **17**, 39719–39731.
- 202 L. Gutiérrez-Gálvez, N. Seddaoui, L. Fiore, L. Fabiani, T. García-Mendiola, E. Lorenzo and F. Arduini, *ACS Sens.*, 2024, **9**, 4047–4057.
- 203 S. Kim, Y. Hao, E. A. Miller, D. M. Y. Tay, E. Yee, P. Kongsuphol, H. Jia, M. McBee, P. R. Preiser and H. D. Sikes, *ACS Sens.*, 2021, **6**, 1891–1898.
- 204 S. Liu, Y. Hou, Z. Li, C. Yang and G. Liu, *ACS Sens.*, 2023, **8**, 3520–3529.
- 205 S. Jackson, S. Lee and A. K. Badu-Tawiah, *Anal. Chem.*, 2022, **94**, 5132–5139.
- 206 B. S. Batule, Y. Seok and M.-G. Kim, *Biosens. Bioelectron.*, 2020, **151**, 111998.
- 207 B. P. Sullivan, A. T. Bender, D. N. Ngyuen, J. Y. Zhang and J. D. Posner, *J. Chromatogr., B*, 2021, **1163**, 122494.
- 208 I. Choopara, A. Suea-Ngam, Y. Teethaisong, P. D. Howes, M. Schmelcher, A. Leelahavanichkul, S. Thunyaharn, D. Wongsawaeng, A. J. Demello, D. Dean and N. Somboonna, *ACS Sens.*, 2021, **6**, 742–751.
- 209 S. Cui, K. Wang, Y. Yang, X. Lv and X. Li, *Anal. Bioanal. Chem.*, 2024, **417**, 785–797.
- 210 E. A. Phillips, T. J. Moehling, K. F. K. Ejendal, O. S. Hoilett, K. M. Byers, L. A. Basing, L. A. Jankowski, J. B. Bennett, L.-K. Lin, L. A. Stanciu and J. C. Linnes, *Lab Chip*, 2019, **19**, 3375–3386.
- 211 L. Bezinge, J. M. Lesinski, A. Suea-Ngam, D. A. Richards, A. J. deMello and C.-J. Shih, *Adv. Mater.*, 2023, **35**, 2302893.
- 212 R. Hiraoka, K. Kuwahara, Y.-C. Wen, T.-H. Yen, Y. Hiruta, C.-M. Cheng and D. Citterio, *ACS Sens.*, 2020, **5**, 1110–1118.
- 213 C. Park, H.-R. Kim, S.-K. Kim, I.-K. Jeong, J.-C. Pyun and S. Park, *ACS Appl. Mater. Interfaces*, 2019, **11**, 36428–36434.
- 214 D. Kim, S. Kim and S. Kim, *Analyst*, 2020, **145**, 5491–5499.
- 215 J. Xu, H. Khan and L. Yang, *Anal. Chem.*, 2021, **93**, 14755–14763.
- 216 J. Cheng, Y. Fu, J. Guo and J. Guo, *Sens. Actuators, B*, 2023, **387**, 133795.
- 217 M. M. P. Melo, A. O. S. S. Rangel and R. B. R. Mesquita, *Talanta*, 2026, **298**, 128865.
- 218 J. Qi, B. Li, D. Lin, Z. Du, L. Fu, X. Wang, Z. Zhang, L. Luo and L. Chen, *Anal. Chem.*, 2023, **95**, 10486–10491.
- 219 S. Arif, M. Hassan, S. Rasheed, N. Ahmad, B. Fatima, S. G. Musharraf and D. Hussain, *Biosens. Bioelectron.*, 2026, **291**, 118025.
- 220 C. Chen, B. Ran, B. Liu, Y. Xiao, G. Tang, T. Shen, J. Liang and Z. Liang, *Microchem. J.*, 2025, **210**, 112966.
- 221 T. Komatsu, M. Maeki, A. Ishida, H. Tani and M. Tokeshi, *ACS Sens.*, 2020, **5**, 1287–1294.
- 222 M. Karimian, K. Dashtian, R. Zare-Dorabei and S. Norouzi, *Anal. Chim. Acta*, 2024, **1285**, 342022.
- 223 K. Phoosawat, K. Khachornsakkul, N. Ratnarathorn, C. S. Henry and W. Dungchai, *ACS Sens.*, 2021, **6**, 3047–3055.
- 224 D. Tu, A. Holderby, J. Dean, S. Mabbott and G. L. Coté, *Anal. Chem.*, 2021, **93**, 4497–4505.

